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Report on the risk assessment of MT-45  
in the framework of the Council Decision 
on new psychoactive substances
About this series
EMCDDA Risk Assessments are publications 
examining the health and social risks of 
individual new psychoactive substances.
The Risk Assessment Report consists of an 
analysis of the scientific and law enforcement 
information available on the new psychoactive 
substance under scrutiny and the implications 
of placing it under control. It is the outcome of 
a meeting convened under the auspices of the 
EMCDDA Scientific Committee.
This process is part of a three-step procedure 
involving information exchange/early warning, 
risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I Foreword
This publication presents the data and findings of the risk assessment on MT-45 
(1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific 
Committee of the EMCDDA on 16 September 2014. 
The Risk Assessment Report, which was submitted to the European Commission and the 
Council of the European Union on 6 October 2014, examined the health and social risks of 
the drug, information on international trafficking and the involvement of organised crime, 
and the potential implications of subjecting the drug to control measures. MT-45 is the 
tenth new psychoactive substance to be risk assessed under the terms of Council 
Decision 2005/387/JHA.
On the basis of the Risk Assessment Report — and on the initiative of the European 
Commission — on 8 October 2015, the Council decided that MT-45 should be subject to 
control measures across the Member States. This decision is the final stage of the three-
step process — early warning, risk assessment and control of new psychoactive 
substances — established by Council Decision 2005/387/JHA. This legal framework 
allows the EU institutions and Member States to act on all new and potentially threatening 
narcotic and psychotropic drugs that appear on the European drug scene, with the 
EMCDDA and Europol, in collaboration with their respective networks, playing a central 
role in the early detection of such substances and the harms caused by their use — 
information that underpins risk assessment and, ultimately, decision-making. 
In this respect we would like to recognise the excellent work done by the networks of the 
EMCDDA, Europol and the EMA — the Reitox national focal points, Europol national units 
and the national competent authorities responsible for medicinal products — who played 
an essential role in collecting and providing national data.
Finally, we would like to thank all the participants in the risk assessment process for the 
high quality of work carried out. The resulting report is a valuable contribution at the 
European level, which gives clear support to political decision-making. 
Professor Dr Gerhard Bühringer 
Chair, Scientific Committee of the EMCDDA
Wolfgang Götz
Director, EMCDDA
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I EMCDDA actions on monitoring and responding to new drugs
The EMCDDA has been assigned a key role in the detection and assessment of new drugs 
in the European Union under the terms of a Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of new psychoactive substances. It 
establishes a mechanism for the rapid exchange of information on new psychoactive 
substances and provides for an assessment of the risks associated with them in order to 
permit the measures applicable in the Member States for the control of narcotic and 
psychotropic substances to be applied also to new psychoactive substances.
The three-step process involves information exchange/early warning, risk assessment and 
decision-making (see below). More detailed information can be found in the section ‘Action 
on new drugs’ of the EMCDDA’s website: 
www.emcdda.europa.eu/activities/action-on-new-drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, 
risk-assessment and control of new psychoactive substances
I. Information exchange
Early-warning system (EWS) EMCDDA–Europol Joint Reports
III. Decision-making Council Decisions on control
II. Risk assessment EMCDDA Risk Assessments
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I  EMCDDA–Europol Joint Report on MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) — a summary
EMCDDA–Europol Joint Report on a new psychoactive substance: MT-45 
(1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) — in accordance with Article 5 of 
Council Decision 2005/387/JHA on the information exchange, risk assessment 
and control of new psychoactive substances
In April 2014, the EMCDDA and Europol examined the available information on a new 
psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine, commonly known 
by the abbreviation `MT-45’, through a joint assessment based upon the following criteria: 
(1) the amount of the material seized; (2) evidence of organised crime involvement; (3) 
evidence of international trafficking; (4) analogy with better-studied compounds; (5) 
evidence of the potential for further (rapid) spread; and (6) evidence of cases of serious 
intoxication or fatalities.
The EMCDDA and Europol agreed that the information available on MT-45 satisfied criteria 
4, and, in particular, criteria 6. The two organisations therefore concluded that sufficient 
information has been accumulated to merit the production of a Joint Report on MT-45 as 
stipulated by Article 5.1 of the Decision. Accordingly, the NFPs, the Europol national units 
(ENUs), the EMA and the World Health Organization (WHO) were formally asked to provide 
the relevant information within six weeks from the date of the request, i.e. by 28 May 2014.
The resulting Joint Report on MT-45 was submitted to the Council, the Commission and 
the EMA on 25 June 2014. The report concluded that the health and social risks, caused by 
the use of, the manufacture of, and traffic in MT-45, as well as the involvement of organised 
crime and possible consequences of control measures, could be thoroughly assessed 
through a risk assessment procedure as foreseen by Article 6 of Council Decision 
2005/387/JHA.
The full text of the Joint Report can be found at:
www.emcdda.europa.eu/publications/joint-reports/MT-45
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European Union drug market. The Council Decision also 
provides for an assessment of the risks associated with these 
new psychoactive substances so that, if necessary, control 
measures can be applied in the Member States (5).
MT-45 was first detected in a seizure by customs authorities in 
Sweden in October 2013, and the Early Warning System was 
formally notified in December 2013. Following an assessment 
of the available information on MT-45, and in accordance with 
Article 5 of the Council Decision, on 25 June 2014 the 
EMCDDA and Europol submitted a Joint Report on MT-45 to 
the Council of the European Union, the European Commission 
and the European Medicines Agency (EMA) (6). Taking into 
account the conclusion of the Joint Report, and in accordance 
with Article 6 of the Council Decision, on 26 September 2014 
the Council formally requested that ‘the risk assessment 
should be carried out by the extended Scientific Committee of 
the EMCDDA and be submitted to the Commission and the 
Council within 12 weeks from the date of this notification’.
In accordance with Article 6.2, the meeting to assess the risks 
of MT-45 was convened under the auspices of the Scientific 
Committee of the EMCDDA with the participation of five 
additional experts designated by the Director of the EMCDDA, 
acting on the advice of the Chairperson of the Scientific 
Committee, chosen from a panel proposed by Member States 
and approved by the Management Board of the EMCDDA. The 
additional experts were from scientific fields that were either 
not represented, or not sufficiently represented on the Scientific 
Committee, and whose contribution was necessary for a 
balanced and adequate assessment of the possible risks of 
MT-45, including health and social risks. Furthermore, two 
experts from the Commission, one expert from Europol and one 
threat to public health comparable to the substances listed in Schedules I, II 
or IV; ‘new psychotropic drug’ means a substance in pure form or in a 
preparation that has not been scheduled under the 1971 United Nations 
Convention on Psychotropic Substances, and that may pose a threat to public 
health comparable to the substances listed in Schedules I, II, III or IV.
(5)  In compliance with the provisions of the 1961 United Nations Single 
Convention on Narcotic Drugs and the 1971 United Nations Convention on 
Psychotropic Substances.
(6)  EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new 
psychoactive substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45), 
EMCDDA, Lisbon.
I Introduction
This Risk Assessment Report presents the summary findings 
and conclusions of the risk assessment carried out by the 
extended Scientific Committee of the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) on the new 
psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)
piperazine, commonly called MT-45. The report has been 
prepared and drafted in accordance with the conceptual 
framework and the procedure set out in the risk assessment 
operating guidelines (1). It is written as a stand-alone 
document that presents a summary of the information 
considered during the detailed analysis of the scientific and 
law enforcement data available at this time. The conclusion of 
the report summarises the main issues addressed and 
reflects the opinions held by the members of the Scientific 
Committee. A list of the information resources considered by 
the Scientific Committee, including a detailed Technical report 
on MT-45, is provided below.
The risk assessment has been undertaken in compliance with 
Article 6 of Council Decision 2005/387/JHA of 10 May 2005 on 
the information exchange, risk assessment and control of new 
psychoactive substances (2) (hereafter the ‘Council Decision’). 
The Council Decision established a mechanism for the rapid 
exchange of information on new psychoactive substances 
(hereafter ‘Early Warning System’ (3)) that may pose public-
health and social risks, including the involvement of organised 
crime. The Council Decision therefore allows the institutions of 
the European Union and the Member States to act on all new 
narcotic and psychotropic substances (4) that appear on the 
(1)  EMCDDA (2009), Risk assessment of new psychoactive substances: 
operating guidelines, Publications Office of the European Union, Luxembourg 
(2)  OJ L 127, 20.5.2005, p. 32.
(3)  The information exchange mechanism laid down by the Council Decision is 
operationalised as the European Union Early Warning System on New 
Psychoactive Substances (‘Early Warning System’). It is operated by the 
EMCDDA and Europol in partnership with the Reitox national focal points and 
Europol National Units in the Member States, the European Commission and 
the European Medicines Agency.
(4)  According to the definition provided by the Council Decision, ‘new 
psychoactive substance’ means a new narcotic drug or a new psychotropic 
drug in pure form or in a preparation; ‘new narcotic drug’ means a substance 
in pure form or in a preparation that has not been scheduled under the 1961 
United Nations Single Convention on Narcotic Drugs, and that may pose a 
Risk Assessment Report of a new 
psychoactive substance: 1-cyclohexyl-4-
(1,2-diphenylethyl)piperazine (MT-45)
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expert from the European Medicines Agency (EMA) participated 
in the risk assessment. For logistical reasons, the meeting took 
place on 16 September 2014 at the EMCDDA in Lisbon, with 
the Risk Assessment Report being completed after the formal 
request from the Council was received by the EMCDDA. The 
risk assessment was carried out on the basis of information 
provided to the Scientific Committee by the Member States, the 
EMCDDA, Europol and the EMA. A list of the extended Scientific 
Committee and the other participants attending the risk 
assessment meeting is included at the end of this publication. 
The extended Scientific Committee considered the following 
information resources during the risk assessment:
 i.  Technical report on 1-cyclohexyl-4-(1,2-diphenylethyl)
piperazine (MT-45) (Annex 1);
 ii.  EMCDDA–Europol Joint Report on a new psychoactive 
substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine 
(MT-45);
 iii.  scientific articles, official reports and grey literature, and 
Internet drug discussion forums and related websites 
(hereafter ‘user websites’);
 iv.  data from EMCDDA monitoring of Internet suppliers 
(which typically appear to be manufacturers and/or 
wholesalers) and retailers selling MT-45;
 v.  Risk assessment of new psychoactive substances: 
operating guidelines; and 
 vi.  Council Decision 2005/387/JHA of 10 May 2005 on the 
information exchange, risk assessment and control of new 
psychoactive substances.
Finally, it is important to note that this Risk Assessment 
Report contains a discussion of the available information on 
non-fatal intoxications and deaths associated with MT-45. 
Such information is critical to the identification of emerging 
toxicological problems associated with new psychoactive 
substances within the European Union. In this context, it is 
important to recognise that the capacity to detect, identify 
and report these events differs both within and between 
Member States. Some Member States have introduced 
programmes in the past few years to strengthen these 
capacities. As a result, more information is available; however, 
it is likely that serious adverse events remain under-detected.
I  Physical, chemical and pharmacological description of MT-45 and its mechanism of action, including its medical value
MT-45 is an N,N ’-disubstituted piperazine, having a 
cyclohexane ring attached to one of the nitrogen atoms of the 
piperazine ring and a 1,2-diphenylethyl moiety attached to the 
other nitrogen atom (Figure 1). MT-45 is one of a series of 
1-(1,2-diphenylethyl)piperazine analgesics invented in the 
early 1970s. Its systematic (International Union of Pure and 
Applied Chemistry, IUPAC) name is (1-cyclohexyl-4-(1,2-
diphenylethyl)piperazine. Another abbreviation encountered in 
the literature is I-C6 (7).
The free amine of MT-45 is a colourless solid; the 
hydrochloride salt of MT-45 is also a solid. Seizures and 
collected samples within the European Union have usually 
noted the presence of MT-45 in white powder form; it is 
unknown whether the samples contained the free amine or a 
salt. MT-45 contains an asymmetry centre, thus it is a chiral 
molecule. Studies on MT-45 from the literature have found 
that the pharmacological effects of racemic MT-45 and its (S) 
and (R) enantiomers were somewhat different. The 
stereoisomeric composition of the MT-45 that is on the drug 
market within the European Union is currently unknown, but 
evidence from Japan suggests that the products sold in 
Europe are most likely racemic. 
MT-45 is typically administered orally or by nasal insufflation; 
the vapours of the heated free base can be inhaled while the 
water-soluble hydrochloride salt can be administered by 
injection.
The tentative single doses reported by users are 15–30 mg for nasal 
intake and 25–75 mg for oral administration; re-dosing is common. 
The desired effects reportedly manifest within 15 minutes
FIGURE 1
The molecular structure, formula and weight of MT-45. 
Asterisk indicates chiral centre
*
N
N
Molecular formula: C
24
H
32
N
2
Molecular weights: 348.52 (base); 421.45 (2 x HCl salt)
(7)  In the name I-C6, ‘I’ refers to structural ‘Group I’, while ‘C6’ indicates the 
six-membered cyclohexane ring in the molecule.
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of nasal intake or within 60 minutes of oral intake and may last 
for up to two hours; re-dosing may extend the effects.
Detailed information on the analytical profile of MT-45 is 
provided in Annex 1. Briefly, the detection (8) of MT-45 by gas 
chromatography and liquid chromatography coupled with 
mass spectrometry is straightforward. Infrared spectroscopy 
may also be used for the analysis of MT-45 in bulk samples. 
There is no information on presumptive colour tests with 
MT-45. No immunoassay field test for MT-45 is currently 
available. MT-45 does not appear to show cross-reactivity in 
standard drug immunoassay tests. Analytical reference 
materials facilitating the quantification of MT-45 in biological 
matrices are available. 
No data are available on the pharmacokinetics of MT-45, and 
no metabolites of the substance have been identified.
There have been several animal model studies and in vitro 
experiments investigating the pharmacodynamics, in particular 
the analgesic mode of action of racemic MT-45 as well as the 
individual (S) and (R) enantiomers. Studies with rodents 
established racemic MT-45 and the (S)-MT-45 enantiomer to 
be opioid-like analgesics, with the (S) isomer being more potent 
than morphine in most rodent assays. In a receptor study, 
(S)-MT-45 appeared to be an opioid receptor agonist showing 
selectivity towards the δ and κ opioid peptide (DOP and KOP, 
respectively) receptor types, and with affinities comparable to 
or higher than those of morphine. The (R) isomer, however, 
displayed lower potency and diminished selectivity.
Knowledge of the activity of MT-45 at pharmacological targets 
other than the opioid system is limited. In mice, the (R) isomer 
of MT-45 induced learning and memory impairment that was 
independent of the opioid system and was due to antagonism 
at sigma receptors.
Studies on the side effect and adverse effect profiles of MT-45 
in rodents and rabbits revealed opioid-like adverse effects, 
including respiratory depression and constipation.
The acute toxicity of MT-45 upon oral or intravenous 
administrations to rodents is several-fold higher than that of 
morphine.
There are no clinical studies on the (psycho)pharmacological 
effects of MT-45 in humans. Self-reported experiences from 
user websites and information from non-fatal intoxications 
(8)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, 
etc.) and/or other specimens (tissues, hair, etc.).
and deaths associated with the substance suggest that its 
effects are similar to those of other opioids.
MT-45 is available as an analytical reference standard and for 
use in scientific research. There are no known uses of MT-45 
as a component in industrial, cosmetic or agricultural 
products. There are currently no other indications that MT-45 
may be used for other legitimate purposes.
MT-45 has no established or acknowledged medical value or 
use (human or veterinary) in the European Union. There is no 
marketing authorisation (existing, ongoing or suspended) for 
MT-45 in the European Union or in the Member States that 
responded to the information request by the EMA that was 
launched under Article 5 of the Council Decision. In addition, 
there is no information that MT-45 is used for the manufacture 
of a medicinal product or an active pharmaceutical ingredient 
(API) of a medicinal product in the European Union. It is 
important to note that the data collection is incomplete and 
some countries indicated that this information is not known. 
The EMA reported that it is not known if MT-45 is used in the 
manufacture of medicinal products for human or veterinary 
use in the European Union. It should be noted that there is no 
European Union database on the synthetic routes of all 
registered medicinal products. Therefore, the use of MT-45 
cannot be ruled out with certainty.
I  Chemical precursors that are used for the manufacture of MT-45
There is no information regarding the manufacturing sites, the 
precursors or the synthetic methods employed for MT-45 
detected on the drug market within the European Union. As 
such, the impurities and side-products are also unknown.
In the 1970s two methods for the synthesis of MT-45 and its 
closely related analogues were published in the scientific and 
patent literature (9). In one of the methods, the key precursor is 
the commercially available racemic 1,2-diphenylethylamine, 
from which MT-45 is obtained by ring-forming alkylation with 
N,N-bis(2-chloroethyl)cyclohexanamine, which must be 
prepared separately (10). Alternatively, MT-45 can be prepared 
by ring-forming alkylation of cyclohexylamine with N,N-bis(2-
chloroethyl)-1,2-diphenylethanamine, which is obtained by a 
multi-step process. 
(9)  It may be noted that later syntheses of analogues of MT-45 relied on 
alternative routes that may, in principle, be used for ‘nitrogen mustard-free’ 
production of MT-45.
(10)  Such bis(2-chloroethyl)amine derivatives (nitrogen mustards) are dangerous 
(blister-producing) substances.
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Precursors and other chemicals needed for the manufacture 
of MT-45 are inexpensive and are readily available or can be 
routinely prepared. The procedures require conventional 
equipment and, apart from necessary precautions when using 
toxic synthetic intermediates (11), no specialised chemical 
expertise is needed for the production of the substance.
I Health risks associated with MT-45
I Individual health risks
The assessment of individual health risks includes 
consideration of the acute and chronic toxicity of MT-45, its 
dependence potential and its similarities to and differences 
from other chemically or pharmacologically related 
substances.
It is important to note, when interpreting the information on 
non-fatal intoxications and deaths reported by Member States 
and information from user websites, that individuals may have 
used other pharmacologically active substances in addition to 
MT-45. The presence of and/or interaction with other 
substances may account for some of the reported effects.
The acute toxicity of MT-45 has been assessed in rodents. In 
general, MT-45, regardless of stereoisomeric composition, is 
several-fold more toxic to rodents than morphine. For 
example, upon oral administration to rats the median lethal 
(LD
50
) values for racemic MT-45 and morphine are 150 and 
335 mg/kg, respectively. Data from some experimental pain 
models in mice suggests that the difference between 
analgesic and toxic doses for MT-45 are smaller than those for 
morphine, indicating higher risk of overdose. It was observed 
that in sub-lethal doses the racemic mixture and the (S) 
isomer caused excitation, whereas the (R) isomer caused 
sedation, which is consistent with in vitro studies suggesting 
different modes of action for the individual stereoisomers.
No human studies were identified that investigated the 
pharmacological or behavioural effects of MT-45. Information 
on adverse effects from non-fatal intoxications and deaths is 
discussed below.
Based on users’ self-reports, the effects of MT-45 resemble 
those of classical opioids, with feelings of mild euphoria and 
relaxation; miosis, sweating, itching and nausea appear to be 
typical adverse effects. Self-medication with MT-45 to relieve 
(11)  See footnote 10 on the toxicity of nitrogen mustards.
pain or to alleviate withdrawal symptoms due to cessation of 
the use of another opioid has also been reported.
A total of 18 non-fatal intoxications associated with MT-45, of 
which 12 were analytically confirmed, have been reported by a 
single Member State, Sweden. The typical clinical features 
included miosis, tachycardia, somnolence, unconsciousness, 
decreased respiratory rate and cyanosis. In some cases 
neurological disturbances such as paraesthesia, blurred vision 
and bilateral hearing loss were also noted.
In life-threatening intoxications the administration of the 
opioid receptor antagonist naloxone may be valuable in 
reversing overdose features.
Twenty-eight deaths associated with MT-45 have been 
reported by a single Member State, Sweden, all of which were 
analytically confirmed. These deaths occurred within a 
nine-month period between November 2013 and July 2014, 
typically in a home environment; the routes of drug 
administration are not known. 
In 19 deaths MT-45 was reported either as the cause of death 
or as contributing to death (even in presence of other 
substances); in three of these deaths MT-45 was the sole drug 
present. In eight deaths MT-45 may have contributed to 
toxicity but other substances were present that may have 
been more toxicologically significant. An alternative cause of 
death was recorded in one case (the deceased had jumped off 
a building). In the cases where other substances were found 
these included opioids, benzodiazepines (both authorised 
medicinal products and unauthorised products), stimulants 
and other prescription medicines (including antipsychotics, 
antidepressants and anticonvulsants) (12).
Data from animal models suggest that MT-45 may have a 
dependence potential in humans. The opioid receptor 
antagonist nalorphine elicited withdrawal signs similar to 
those noted for morphine in mice that had received repeated 
doses of MT-45. Furthermore, MT-45 substituted for morphine 
in morphine-dependent rats. No self-administration studies in 
animals have been published.
No studies have examined the abuse and dependence 
potential of MT-45 in humans. A limited number of self-
reported user experiences suggest the development of mild 
withdrawal-like symptoms.
(12)  Authorised medicinal products are those medicines that have received a 
marketing authorisation by a competent authority within the EU, e.g. 
diazepam and alprazolam. Benzodiazepines that have not received such 
authorisation include diclazepam, pyrazolam and flubromazepam, all of 
which have appeared on the new psychoactive substance market in recent 
years.
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There is no information regarding the sites or the methods 
used to manufacture MT-45 detected in the Member States. 
Suppliers that advertise MT-45 on the Internet, including 
wholesale amounts, might not necessarily be the 
manufacturers of the chemical.
I  Information on any assessment of MT-45 in the United Nations system
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the 1961 Single Convention on Narcotic 
Drugs and the 1971 Convention on Psychotropic Substances. 
On 14 May 2014 the World Health Organization informed the 
EMCDDA that MT-45 is currently not under assessment and 
has not been under assessment by the United Nations system, 
and that no such assessment is planned.
I  Description of the control measures that are applicable to MT-45 in the Member States
MT-45 is not listed for control in the 1961 UN Single 
Convention on Narcotic Drugs and the 1971 United Nations 
Convention on Psychotropic Substances (together ‘UN drug 
conventions’).
One Member State (Sweden) reported that MT-45 is subject 
to control measures under drug control legislation that is in 
accordance with the UN drug conventions. The remaining 27 
Member States, Turkey and Norway do not control MT-45 
under such legislation; however, seven Member States 
(Austria, Ireland, Latvia, the Netherlands, Poland, Romania and 
Spain) reported other legislative measures that control MT-45.
Sweden reported that MT-45 is a controlled narcotic 
substance (SFS 2014:1032; in force since 19 August 2014) 
according to the Act on the Control of Narcotic Drugs.
Austria, Ireland, Latvia, Poland and Romania reported that 
MT-45 is controlled under legislation prohibiting the 
unauthorised supply of defined or qualifying new psychoactive 
substances. In Austria MT-45 is controlled under the new 
psychoactive substances law (NPSG, Group II), categorised as 
member of the ‘(1-phenyl and 1-benzyl)piperazine’ group. In 
Latvia MT-45 is controlled by being placed under temporary 
control for 12 months (control in force since 15 May 2014) by 
the decision of the Centre for Disease Prevention and Control 
according to the Law on Procedures for the Legal Trade of 
Narcotic and Psychotropic Substances and Medicinal 
Products. Laws were passed in Ireland (in 2010), Poland 
(2010) and Romania (2011) that prohibit the unauthorised 
supply of any psychoactive substance that qualifies by 
conforming to certain criteria. It was reported that national 
authorities may find that MT-45 meets such criteria. Of those, 
Poland reported that MT-45 falls under the definition of a 
‘substitution drug’ under the Act amending the Act on 
counteracting drug addiction and the Act on State Sanitary 
Inspection, 2010 and as such its marketing and production 
may be subject to an administrative fine.
In the Netherlands, the sale of MT-45 may be subject to 
control under the Commodities Act, which describes the rules 
for food and consumer products to safeguard public health. It 
provides for both administrative and custodial penalties for 
offences. 
Spain reported that, although there is no current specific 
legislation controlling production, commerce, imports, exports 
or use/consumption of this substance, given that it may cause 
harmful effects to those using it there is general legislation on 
consumer health protection that is fully applicable, if 
necessary.
Twenty Member States (Belgium (13), Bulgaria, Croatia, 
Cyprus, the Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Italy, Lithuania, 
Luxembourg, Malta, Portugal, Slovakia, Slovenia and the 
United Kingdom), Turkey and Norway reported that MT-45 is 
not subject to control measures at the national level.
I  Options for control and the possible consequences of the control measures
Under Article 9.1 of the Council Decision, the option for 
control that is available at European Union level is for the 
Member States to submit the new psychoactive substance 
MT-45 to control measures and criminal penalties, as provided 
for under their legislation, by virtue of their obligations under 
the UN drug conventions. There are no studies on the possible 
consequences of such control measures on MT-45. If this 
(13)  Belgium reported that MT-45 is included in the new generic drug legislation 
that will come into effect in 2014 once the Royal decree has been signed. 
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There are no data on the interaction of MT-45 with other 
substances, including medicinal products. In this context, it is 
worth noting that the sedative effects of opioid analgesics are 
enhanced when used with antipsychotics and central nervous 
system depressants including hypnotics, anxiolytics, tricyclic 
antidepressants and sedating antihistamines.
There is no information on the psychosocial consequences of 
(chronic) use of MT-45.
No studies have been published on the neurotoxicity, 
reproductive toxicity, genotoxicity or carcinogenic potential of 
single or repeated doses of MT-45. No studies have examined 
the chronic toxicity of MT-45 in animals or humans.
I Public health risks
The public health risks associated with MT-45 may be 
categorised in terms of: pattern of use (extent, frequency, 
route of administration, etc.); availability and quality of the 
drug; availability and degree of information relevant to the 
effect of the drug amongst users; and negative health 
consequences.
According to user reports, MT-45 appears to have been 
available since 2012. It is openly marketed on the Internet as a 
‘research chemical’. Since October 2013, when MT-45 was 
first detected in Sweden, two additional Members States have 
reported detections (Belgium and Germany). EMCDDA 
monitoring of Internet suppliers and retailers identified twelve 
sites, some apparently based in the European Union that 
offered MT-45 for sale, including in kilogram quantities.
As noted, the preferred route of administration appears to be 
oral and nasal. Injection has also been reported. In such 
instances, sharing of needles and syringes carries the risk of 
transmission of blood-borne viruses. People who 
experimented with the drug often reported repeated intake of 
MT-45 to maintain its effects for up to eight hours. Similar to 
other drugs, MT-45 may be combined with other psychoactive 
substances by users.
There are no prevalence data on the use of MT-45 in the 
European Union or elsewhere, but available information does 
not suggest widespread use of the substance. Based on the 
available information, MT-45 is mostly used in a home 
environment either by people who experiment with any drug 
that is new and readily available (such as ‘psychonauts’) or 
opioid-dependent users who have no access to heroin or any 
other opioid.
Based on limited information available on user websites, it 
appears that, as with any new psychoactive substance, 
vendors and (potential) users rely on non-professional 
information about MT-45, such as user reports that are 
accessible on the Internet. Forum discussion participants 
appear to be generally aware of the opioid-like (wanted and 
unwanted) effects of and risks associated with the use of 
MT-45.
I Social risks associated with MT-45
There is limited information on the social risks associated with 
MT-45.
There is no information on whether the use of MT-45 affects 
education or career, family or other personal or social 
relationships, including marginalisation.
Although there are no relevant studies, it may be assumed 
that the acute behavioural (e.g. sedative) effects of MT-45 on 
operating machinery and driving are of a similar impairing 
nature to those caused by other opiate-type narcotic 
analgesics.
Data related to the social risks associated with the distribution 
and trafficking of MT-45 are lacking.
It is not possible at this time to estimate whether the use of 
MT-45 is associated with greater healthcare costs than other 
opioid drugs.
I  Information on the level of involvement of organised crime, seizures and/or detections by the authorities, and the manufacture of MT-45
MT-45 was first identified in a seizure of 49.9 g by customs 
authorities in Sweden in October 2013 and reported to the 
Early Warning System in December 2013. Since then 
Germany has also reported two seizures of 11.3 g and 250.5 g; 
in the former, MT-45 was detected as a component of a 
sample of brown heroin base. Belgium also reported the 
detection of MT-45 in a sample that also contained methylone.
There is no specific information to suggest the involvement of 
organised crime or criminal groups in the manufacture, 
distribution and supply of MT-45. It is noted that the largest 
seizure of MT-45 reported so far was 250 g; this is not 
indicative of large-scale organised trafficking.
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option of control is pursued, the Committee considers that the 
following consequences are possible. Some of these may 
apply to any new psychoactive substance. 
n  This control option could be expected to limit the 
availability of MT-45 and hence the further expansion of 
the current open trade in this substance within the 
European Union. However, this may have little impact on 
the manufacturers and suppliers outside of this 
jurisdiction.
n  A health consequence that might result from this control is 
the benefit brought about by the presumed reduction of 
availability and use of MT-45.
n  This control option could facilitate the detection, seizure 
and monitoring of MT-45 related to its unlawful 
manufacture, trafficking and use by facilitating cooperation 
between the judicial authorities and law enforcement 
agencies across the European Union.
n  This control option would imply additional costs for the 
criminal justice system, including forensic services, law 
enforcement and the courts.
n  This control option could lead to replacement with 
structurally related or other (established or new) 
psychoactive substances that may also have public health 
consequences.
n  This control option is not expected to impact on current 
and future research by the pharmaceutical or chemical 
industries.
n  This control option could create an illicit drug market in 
MT-45 with increased risk of associated criminal activity, 
including organised crime.
n  It is not expected that this control option could impact on 
the quality/purity of any MT-45 still available on the market. 
However, it is of concern that Internet retailers within the 
European Union may offer price discounts or other 
promotions in order to dispose of remaining stocks of 
MT-45 when control measures are imminent. Therefore, 
this control option could lower the price of any MT-45 that 
is still available on the market and temporarily increase its 
availability. The extent to which this will impact on public 
health, criminality or levels of use is difficult to predict.
In order to examine the consequences of control, the 
Committee wishes to note that it will be important to monitor 
for the presence of MT-45 on the market post-control, should 
this option be pursued.
Aside from the option for control under those stipulated in 
Article 9.1 of the Council Decision, other options for control 
may be available to the Member States. These may include 
restricting the importation and supply of the substance, as 
some Member States have already done.
I Conclusions
MT-45 is a synthetic opioid investigated as an analgesic in the 
1970s. Its structure is unique and contains a piperazine core 
bearing a cyclohexyl group on one of the nitrogen atoms and a 
1,2-diphenylethyl moiety on the other. The dihydrochloride salt 
of MT-45 is typically found as a powder. The substance is 
administered orally, by nasal insufflation, or, to a lesser extent, 
by injection or inhaling the vapours of its free base.
Animal model studies and experiments in vitro established 
MT-45 to be an opioid receptor agonist with analgesic potency 
similar to or higher than morphine in some pain models. 
Animal studies indicate that the adverse-effect profile of 
MT-45 is similar to that of morphine. The acute toxicity, 
including the respiratory inhibitory effect, of MT-45 is higher 
than that of morphine. 
Data from animal models suggest that MT-45 may have a 
dependence potential in humans. The pharmacological and 
behavioural activities of MT-45 in humans have not been 
studied. Limited information available from non-fatal 
intoxications and deaths and from user websites indicates 
that the physiological and psychological effects of MT-45 are 
similar to those of opioids.
The substance has no recognised medical (human or 
veterinary) use in the European Union nor, it appears, 
elsewhere. There are no indications that MT-45 may be used 
for any other purpose aside from as an analytical reference 
standard and in scientific research.
MT-45 has emerged on the new psychoactive substances 
market where it is sold as a ‘research chemical’. It appears to 
be mostly sold on the Internet. MT-45 was first detected in a 
powder by Swedish customs in October 2013 and was 
formally reported to the Early Warning System in December 
2013; since then, two other Member States have reported 
detections of the substance. In general, analyses of seizures 
have found MT-45 to be the sole psychoactive substance 
present. In a few small seizures, however, other controlled 
drugs or new psychoactive substances have been detected: 
Germany reported MT-45 in a seized sample of brown heroin; 
Belgium reported the detection of MT-45 along with 
methylone in a collected powder; Sweden reported the 
detection of MT-45 along with synthetic stimulants in two 
powder samples and along with synthetic cannabinoids in two 
herbal preparations.
In the non-fatal intoxications reported by Sweden, the clinical 
features were similar to those of opioid intoxication and in 
some cases responded to the opioid receptor antagonist 
naloxone. 
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A total of 28 deaths where the presence of MT-45 in biological 
samples was analytically confirmed have been reported by a 
single Member State, Sweden. These deaths occurred within a 
nine-month period between November 2013 and July 2014, 
typically in a home environment, but information on the route 
of administration is lacking. 
In 19 of the deaths MT-45 was reported as either the cause of 
death or contributing to death (even in presence of other 
substances); in three of these deaths MT-45 was the sole drug 
present. In eight deaths MT-45 may have contributed to 
toxicity but other substances were present that may have 
been more toxicologically significant. An alternative cause of 
death was recorded in the one remaining case (the deceased 
jumped off a building). In the cases where other substances 
were found these included opioids, benzodiazepines (both 
authorised medicines and unauthorised), stimulants and other 
prescription medicines (including antipsychotics, 
antidepressants and anticonvulsants).
There are no prevalence data on the use of MT-45. Limited 
information suggests that there may be some interest in using 
MT-45 among people who are familiar with licit or illicit 
opioids. It is often used in combination with other 
psychoactive substances. However, further information on the 
size, demand and characteristics of these groups of people is 
not available. There is no specific information on the social 
risks that may be related to MT-45.
There is no specific information to suggest the involvement of 
organised crime in the manufacture, distribution (trafficking) 
and supply. There is no information to suggest that MT-45 is 
currently manufactured in any of the Member States. The 
chemical precursors and the synthetic routes used to 
manufacture the MT-45 detected in Member States are 
unknown. The starting materials used in the documented 
synthetic route are commercially available and not under 
international control.
MT-45 is not listed for control in the 1961 United Nations 
Single Convention on Narcotic Drugs or in the 1971 United 
Nations Convention on Psychotropic Substances. MT-45 is not 
undergoing assessment by the United Nations system. One 
Member State controls MT-45 under drug control legislation 
and seven Member States control MT-45 under other 
legislation.
Many of the questions posed by the lack of evidence on the 
health and social risks of MT-45, as for any new psychoactive 
substance, could be answered through further research. Areas 
where additional information would be important include: 
prevalence and patterns of use (including targeted studies 
that examine user groups and risk behaviours); market studies; 
chemical profiling studies; receptor profiling studies; 
metabolic pathway studies; behavioural studies; clinical 
patterns of acute and chronic toxicity in humans; the potential 
interaction between MT-45 and other substances; the 
dependence and abuse potential in humans; and the social 
risks associated with its use.
The Committee notes that a decision to control MT-45 has the 
potential to bring with it both intended and unintended 
consequences. Potential intended consequences include 
reduced levels of availability and ultimately use. This may 
reduce the health and social risks and consequences arising 
from the use of MT-45. It is important to recognise that a 
potential unintended consequence of control may be the 
manufacture and availability of other substances. Although 
information is limited both on the human (psycho)
pharmacological effects that may make MT-45 appealing and 
on the prevalence of its use, the emergence of chemically 
analogous substances to replace MT-45 is a possibility. The 
implementation of control measures may also lead to the 
criminalisation of those who continue to use this substance 
with the possible attendant risks of socio-economic 
stigmatisation and marginalisation. Finally, control measures 
should not inhibit the gathering and dissemination of accurate 
information on MT-45 to users, practitioners and decision-
makers. 
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experimenting with this new substance. Routes of 
administration are oral, nasal, intravenous or intramuscular 
injection; inhalation of the vapours of the free amine has also 
been mentioned. Typical single oral or nasal doses range from 
30 to 75 mg.
The pharmacology, with special emphasis on analgesic 
effects, of racemic MT-45 and the individual (S) and (R) 
enantiomers has been studied in several animal models. 
Studies with opioid receptor preparations have also been 
carried out. Racemic MT-45 and its (S) isomer appear to be 
morphine-like opioid analgesics with the dextrorotatory (S) 
isomer being more potent than morphine in most rodent 
assays, regardless of the route of administration. One receptor 
study has revealed that (S)-MT-45 is an opioid receptor 
agonist with selectivity towards the d and k opioid peptide 
(DOP and KOP, respectively) receptor types, with affinities 
comparable to or higher than those of morphine. It appears 
that the high analgesic activity of the racemic mixture is due 
to synergistic interactions of the individual stereoisomers. It is 
also conceivable that some of the metabolites contribute to 
analgesic activity in vivo of MT-45, though the metabolism of 
MT-45 is not known.
The levorotatory (R) isomer of MT-45 has been shown to 
induce learning and memory impairment in mice that is 
associated with its antagonism at sigma receptors.
There are no clinical studies on the subjective effects of 
MT-45 in humans. According to self-reports available on 
Internet forums, the effects of MT-45 resemble those of 
opioids.
Information on the dependence liability of MT-45 is limited. 
Studies involving rodent models indicate that MT-45 can 
substitute for morphine; withdrawal symptoms could also be 
induced.
The acute toxicity of MT-45 upon oral and intravenous 
administration to rodents is higher than that of morphine. 
I Summary
MT-45 is an N,N ’-disubstituted piperazine having a 
cyclohexane ring attached to one of the nitrogen atoms of the 
piperazine ring and a 1,2-diphenylethyl moiety attached to the 
other nitrogen atom. MT-45 was invented by the Japanese 
company Dainippon Pharmaceutical Co. Ltd in the early 
1970s. The analgesic properties of MT-45 were studied in 
pre-clinical trials in the 1970s and the 1980s, but the drug 
was not developed into a medicine. MT-45 has no current 
known legitimate industrial, agrochemical, cosmetic, human 
or veterinary medical use.
MT-45 has appeared recently on the illicit drug market, 
typically as a white powder. It is offered for sale on the 
Internet. It was first detected (1) in a seizure by customs 
authorities in Sweden in October 2013, and was formally 
notified to the European Union Early warning system in 
December 2013. MT-45 has also been detected in Germany 
and Belgium. Most of the seizures have been reported by 
Sweden; the largest seizure (250 g) was reported by 
Germany.
According to experience reports posted on the Internet, 
MT-45 appears to have been available since 2012. It is 
advertised for sale on its own as a ‘research chemical’ or a 
‘legal opioid’ in amounts ranging from gram to kilogram 
quantities.
Due to the lack of coordinated national or European 
population surveys related to MT-45, there is no information 
on the prevalence of its use.
Information from self-reports posted on Internet forums 
indicates that many of the users of MT-45 appear to be only 
(1)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, 
etc.) and/or other specimens (tissues, hair, etc.).
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Typical opioid type adverse effects, including respiratory 
depression and constipation, were noted in rodent studies.
Eighteen non-fatal intoxications were reported from a single 
Member State, Sweden; 12 of these were analytically 
confirmed. In life-threatening intoxications the opioid receptor 
antagonist naloxone was valuable in reversing overdose 
symptoms.
Twenty-eight deaths where MT-45 was analytically confirmed 
post mortem have been reported. All occurred in Sweden 
between November 2013 and July 2014. In 19 deaths MT-45 
was reported either as the cause of death (8 cases) or as 
contributing to death (even in presence of other substances); 
in three of these deaths MT-45 was the sole drug present. In 
eight deaths MT-45 may have contributed to toxicity but other 
substances were present that may have been more 
toxicologically significant. An alternative cause of death was 
recorded in one case. 
In conclusion, MT-45, first described in the scientific 
literature in 1975, is a recently emerged synthetic opioid 
analgesic with a novel chemical structure. The powder 
products currently sold are presumed to be racemic mixtures 
of the hydrochloride salts of (S) and (R) stereoisomers of 
MT-45. The pharmacological properties of MT-45, including 
dependence liability and toxicity, are similar to morphine. 
Currently, the use of MT-45 in European Union (EU) Member 
States, Norway and Turkey appears to be limited. Between 
October 2013 and July 2014 MT-45 was seized in two 
Member States, Sweden and Germany; it was also detected 
in a single sample in Belgium. Fatal and non-fatal 
intoxications, occurring within a period of six months, have 
been reported from a single EU Member State, Sweden. 
Between November 2013 and April 2014 MT-45 was 
detected in a number of non-fatal poisonings. There have 
been 28 deaths where MT-45 was detected post mortem. In 
19 deaths MT-45 was reported either as the cause of death 
(8 cases) or as contributing to death (even in presence of 
other substances).
I  Section A. Physical, chemical, pharmaceutical and pharmacological information
I  A1. Physical, chemical and pharmaceutical information 
A1.1. Physical and chemical description 
(including methods of synthesis, precursors, 
impurities if known — type and level)
Chemical description and names 
MT-45 is an N,N ’-disubstituted piperazine compound, having a 
cyclohexane ring attached to one of the nitrogen atoms of the 
piperazine ring and a 1,2-diphenylethyl moiety attached to the 
other nitrogen atom (Figure 1).
MT-45 is a structurally unique synthetic analgesic developed 
by the Japanese company Dainippon Pharmaceutical Co. Ltd 
in the early 1970s while searching for analogues of the 
tricyclic tranquilizer-antipsychotic perathiepine (2) and of the 
structurally related analgesic lefetamine (3) (Umemoto et al., 
1972; Natsuka et al., 1975; Nishimura et al., 1976; see also 
Hori and Fujimura, 1975). The pharmacological properties of 
MT-45 were studied by industrial and academic laboratories in 
the 1970s and 1980s in animals and in vitro; it would appear 
(2)  1-(10,11-Dihydrodibenzo[b,f]thiepin-10-yl)-4-methylpiperazine.
(3)  Lefetamine, that is (1R)-N,N-dimethyl-1,2-diphenylethanamine, is controlled 
under the UN 1971 Convention on Psychotropic Substances as a Schedule IV 
substance. It is also called (–)-SPA.
FIGURE 1
The molecular structure, formula and weight of MT-45. 
Asterisk indicates chiral centre
*
N
N
Molecular formula: C
24
H
32
N
2
Molecular weights: 348.52 (base); 421.45 (2 x HCl salt)
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that it has not been studied in humans. These experiments 
revealed that the pharmacology, including analgesic activity, 
of MT-45 is complex and may involve not only opioid receptors 
but also non-opioid targets, which have not been fully 
characterised (Section A2). The development of the 
compound was apparently abandoned, for unknown reasons.
The systematic (International Union of Pure and Applied 
Chemistry, IUPAC) name of MT-45 is 1-cyclohexyl-4-(1,2-
diphenylethyl)piperazine.
Other reported names, acronyms or synonyms: MT-45 (4); 
I-C6 (5); IC-6; CDEP; NSC299236 (6).
One Member State (Belgium) reported that the street name 
‘wow’ has been used in reference to a combination of MT-45 
with a synthetic cathinone analogue methylone (7).
MT-45 is a chiral molecule with one asymmetry centre, thus 
two enantiomers exist. The pure isomers may be obtained by 
resolution of the racemic mixture obtained by synthesis. The 
optical rotation ([α]22
D
 values) determined for the 
dihydrochloride salts of (R)-(–) and (S)-(+) isomers are –56.0 
(c 1.0, methanol) and +56.3 (c 2.0, methanol), respectively 
(Natsuka et al., 1975). There is no information on the isomeric 
composition of the samples seized in the EU, reflecting, in 
part, the fact that stereochemical analysis is not routinely 
undertaken in forensic laboratories. Of note in this respect is 
that no optical rotation was observed for MT-45 isolated from 
a collected sample of a colourless ‘liquid aroma’ drug product 
purchased in Japan in early 2013, indicating that the product 
contained the racemic mixture (Uchiyama et al., 2014).
The Chemical Abstract Service Registry Numbers (CAS RNs) 
for MT-45 (8):
52694-55-0 racemic free base
57314-55-3 dihydrochloride (2 x HCl) salt
57377-70-5 (R)-isomer
57426-38-7 (R)-isomer dihydrochloride salt
52694-52-7 (S)-isomer
52694-54-9 (S)-isomer dihydrochloride salt
(4)  It has not been possible to ascertain the origin of the commonly used name 
MT-45.
(5)  In this acronym, used in the scientific and patent literature, the Roman 
numeral ‘I’ refers to structural ‘Group I’ studied, while ‘C6’ indicates the 
‘six-membered cyclohexane’ ring.
(6)  The “NSC number” is a Cancer Chemotherapy National Service Center 
assigned number from the National Cancer Institute of the United States of 
America.
(7)  2-Methylamino-1-[3,4-methylenedioxyphenyl]propan-1-one or 
1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-2-one.
(8)  The CAS RNs were obtained by an exact but not stereodefined structural 
search in the SciFinder® database (CAS, American Chemical Society). Many 
suppliers and Internet databases, including PubChem, ChemSpider and 
Wikipedia, give a CAS RN of ‘41537-67-1’ for MT-45 but this identifier is no 
longer used by CAS for registration purposes.
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) (9) was searched using 
the CAS registry numbers listed above and also 41537-67-1. 
The search returned no results.
Identification and analytical profile
Analysis of MT-45 using gas chromatography (GC) or liquid 
chromatography (LC) coupled with mass spectrometry (MS) is 
straightforward (10) (see also Uchiyama et al., 2014). The 
electron impact mass spectrum of MT-45 contains the 
following characteristic fragments (m/z): 347 [M-1]+, 257 
(base peak), 175, 166, 146, 124, 107, 91 and 55. The 
electrospray ionisation mass spectrum of MT-45 contains the 
following characteristic fragments (m/z): 349 [M+1]+, 182, 181 
and 169 (analytical data reported to the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA)).
The ultraviolet and visible spectrum of MT-45 has λ
max
 value at 
258 nm (Uchiyama et al., 2014).
The Fourier Transform infrared spectrum of the hydrochloride 
salt of MT-45 contains the following characteristic bands: 441, 
531, 558, 696, 748, 760, 780, 905, 916, 934, 1007, 1071, 
1199, 1265, 1274, 1496, 2448, 2562, 2644, 2945, and 3470 
cm-1 (see spectral data submitted to the EMCDDA; see also 
Hori and Fujimura, 1975). 
The proton and 13C nuclear magnetic resonance (NMR) 
spectra used for the structure identification in the first 
detection of the substance in Japan and Sweden are available 
(Uchiyama et al., 2014; analytical data reported to EMCDDA; 
see also Hori and Fujimura, 1975; Imai, 1982).
There is no information on presumptive colour tests with MT-45.
Urinary MT-45 did not show cross-reactivity in standard 
immunoassay urine screening tests for drugs of abuse 
(Helander et al., 2014). As of August 2014 there is no 
immunoassay field test for MT-45.
Certified reference materials of racemic and enantiomerically 
pure MT-45 suitable for forensic analysis and biological 
studies are commercially available (11).
Physical description
The dihydrochloride salt of MT-45, as obtained by 
recrystallization from methanol, is a solid melting at  
270–271 ºC with decomposition; the free amine forms 
(9) echa.europa.eu/information-on-chemicals 
(10) https://db12.designer-drugs.de
(11)  For example, bioreagent.bertinpharma.com or www.caymanchem.com
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colourless prism upon crystallisation from 95 % ethanol and 
has a melting point of 94–95 ºC (Natsuka et al., 1975). 
According to a product information data sheet available from a 
supplier of analytical standards (12), the hydrochloride salt of 
racemic MT-45 is sparingly soluble in water; its solubility in 
chloroform is approximately 1.4 mg/ml.
Methods and chemical precursors used for the 
manufacture of MT-45
There is no information regarding the manufacturing sites, the 
precursors or the synthetic methods used for MT-45 detected 
within the European Union. Furthermore, suppliers that 
advertise MT-45 might not necessarily be the manufacturers 
of the chemical.
The patent and scientific literature describes two methods for 
the synthesis of MT-45 and closely related analogues 
(Natsuka et al., 1975; Nishimura et al., 1978). One of the routes 
is depicted in Figure 2: the key precursor is the commercially 
available racemic 1,2-diphenylethylamine, which is readily 
(12)  www.caymanchem.com/catalog/14082
converted to MT-45 by ring-forming alkylation with N,N-bis(2-
chloroethyl)cyclohexanamine (13), which is prepared from the 
diethanolamine derivative of cyclohexane (Wilson and Tishler, 
1951). Alternatively, MT-45 can be prepared by alkylating 
cyclohexylamine with N,N-bis(2-chloroethyl)-1,2-
diphenylethanamine (14) obtained by a multi-step process 
involving Grignard reaction (Goodson and Christopher, 1950). 
Note that these syntheses afford a 1:1 mixture of the (S) and 
(R) enantiomers each possessing distinct biological activities 
(Section A2). The pure enantiomers used in pharmacological 
studies were obtained by optical resolution of the racemic 
mixture (Natsuka et al., 1975).
The syntheses of MT-45 mentioned above use readily available 
starting materials and require conventional laboratory 
equipment. No special chemical expertise is needed for the 
production of the substance. However, familiarity with special 
precautions that should be taken when handling the ‘nitrogen 
mustard’ intermediate products is a requirement.
Other synthetic methods are also feasible and have, in fact, 
been used for the synthesis of related 1,2-diphenylethylamines 
(13)  The blister-producing bis(2-chloroethyl)amine derivatives (nitrogen 
mustards) should be considered to be dangerous (cytotoxic) substances due 
to their bioalkylating properties.
(14)  See previous footnote on the toxicity of nitrogen mustards.
FIGURE 2
The synthesis of MT-45 according to Natsuka et al. (1975)
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N
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DMF, heating
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(see, for example, Yamakawa, 1960). One of such routes relies 
on the reaction of a benzyl Grignard reagent and an 
α-piperazino-benzonitrile, which can be obtained from 
benzaldehyde, an alkali metal cyanide and the appropriate 
piperazine (Strecker synthesis) (15). A similar, cyanide-free 
synthetic procedure that uses benzaldehyde, a benzyl Grignard 
reagent and an appropriately substituted piperazine as 
precursors may also be applicable (Fray et al., 2006).
Typical impurities encountered in seized samples
There is currently no information available on impurities 
arising from the synthesis of MT-45 in the seized and collected 
samples obtained from the drug market (Section C). For 
seizures reported to the EMCDDA and Europol, the ingredient 
content has usually not been quantified.
Of the 28 seizures made in Sweden, one powder contained a 
synthetic cathinone (α-PBP (16)), while another one contained 
an arylethylamine stimulant (6-APDB (17)). A white powdery 
sample detected in Belgium contained MT-45 and methylone. 
A ‘light brown, chunky substance’ seized in Germany 
contained MT-45, heroin base, caffeine, paracetamol and 
sorbitol. In two plant materials seized in Sweden, MT-45 was 
detected in the presence of the synthetic cannabinoid 
receptor agonist AB-FUBINACA (18) in one case and APINACA 
(AKB-48) (19) in the second case. For details on seized and 
collected samples, see Section C.
During forensic analysis of a range of products purchased in 
Japan between January and March 2013, MT-45 was found 
along with other new psychoactive substances in an herbal 
mixture, in a ‘fragrance powder’ and in two ‘liquid aroma’ 
formulations (Uchiyama et al., 2014).
A1.2. Physical/pharmaceutical form 
A structured search conducted by the EMCDDA of Internet 
suppliers and retailers selling MT-45 (Section C) found that, 
where specified, the substance is offered as the 
dihydrochloride salt form; in most cases the form offered was 
not specified. Self-reported experiences on user websites 
mention the use of the dihydrochloride salt (Bluelight, 2014a; 
Flashback, 2014; Shroomery, 2014).
(15)  This type of a reaction has general applicability for the synthesis of 
phencyclidine and related drugs. Alkali cyanides, however, are highly 
poisonous substances and their manufacture, trade and use require special 
permit.
(16)  1-Phenyl-2-(pyrrolidin-1-yl)butan-1-one
(17)  6-(2-Aminopropyl)-2,3-dihydrobenzofuran or 1-(2,3-dihydro-1-benzofuran-6-
yl)propan-2-amine
(18)  N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide
(19)  N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide or 1-pentyl-N-
(tricyclo[3.3.1.13,7]dec-1-yl)-1H-indazole-3-carboxamide
Information provided from seizures and a collected sample 
reported by the Member States has usually noted the 
presence of MT-45 in powder form. Whether the MT-45 was 
the free amine or a salt has not been reported. Since no 
systematic analysis has been done, it is not known whether 
the substance traded under the name ‘MT-45’ is the free 
amine or its (di)hydrochloride salt. In one instance it was 
detected in a seized sample of brown heroin base. MT-45 has 
also been detected in samples of plant material in the 
presence of synthetic cannabinoid substances. In two 
non-fatal intoxications reported by Sweden the physical form 
used by the patients included a tablet in one case and a 
capsule in the other.
A detailed description of MT-45 seizures and collected 
samples that have been encountered can be found in Table 4 
(Section C).
A1.3. Route of administration and dosage
Information provided by the Member States and obtained 
from user websites suggests that the routes of administration 
for MT-45 include nasal insufflation (‘snorting’), oral intake 
(tablets, capsules or ‘bombing’), smoking, intravenous and 
intramuscular injection, and rectal administration (see also 
Section D1.2 and Tables 6 and 7). Self-reported doses in 
non-fatal intoxications relating to MT-45 use were 100 mg for 
oral and 60 mg for nasal intake (Helander et al., 2014). 
Information from several user websites indicates that a range 
of doses may be used: single oral doses typically ranged from 
25 to 75 mg with re-dosing reported; doses for nasal 
insufflation included 15–30 mg (this route of administration 
was noted by several users to cause painful irritation). One 
user reported inhaling the vapours of MT-45 base made from 
50 mg of the salt; the same user reported rectal 
administration of ‘80 mg of MT-45 salt as the solution’ 
(Bluelight, 2014a). Single acute oral doses as high as 215 mg 
and repeated dosages totalling 500 mg over the course of 12 
hours have also been reported by users. For further details 
see Section D1.2 (see also Bluelight, 2014a; Flashback, 2014; 
Shroomery, 2014).
In non-fatal intoxications associated with MT-45 use, other 
psychoactive substances have also been detected in 
biological samples (Helander et al., 2014; for details, see 
Section D1.2.2). In several of the deaths reported by Sweden, 
forensic analysis of biological samples detected MT-45 in 
conjunction with other new psychoactive substances, 
medicines and/or controlled drugs (details provided in Section 
D1.2.3 and Table 8). Information from user websites also 
suggests that MT-45 may be used on its own as well as in 
combination with other drugs (Bluelight, 2014a). 
RISK ASSESSMENTS I MT-45
19 / 48
Annex 1
I  A2. Pharmacology, including pharmacodynamics and pharmacokinetics
Pharmacokinetics
There are no data available from animal studies in the 
literature on the pharmacokinetics of MT-45. Likewise, there 
are no data on the metabolic fate of MT-45 in humans.
It is of note that a recent study on the metabolism in the rat of 
structurally related 1,2-diphenylethylamines identified 
aromatic ring hydroxylation as one of the initial metabolic 
steps (Wink et al., 2014). Similar phenolic derivatives could be 
formed from MT-45 as well, and such compounds have been 
prepared and shown to be bioactive (Natsuka et al., 1978; 
Nakamura et al., 1980; Nozaki et al., 1989; Kobayashi, 1991) 
and may contribute to the overall pharmaco-toxicological 
profile of MT-45 in vivo (see also subsection on 
Pharmacodynamics below).
In the absence of studies examining the pharmacokinetics of 
MT-45 in humans, user reports available on the Internet are 
the only source of information relating to the time course of 
the effects of MT-45. According to these self-reports, the 
psychoactive effects of MT-45 become apparent at about 15 
minutes after nasal intake of 30 mg, or at about 60 minutes 
after oral intake of single doses in the range of 45–70 mg; at 
these dosages the effects of MT-45 subside after two hours; 
by re-dosing, which is frequently reported, the effects may be 
extended for over eight hours (Bluelight, 2014a). For examples 
of user reports, see Section D1.2.1.
Pharmacodynamics
The unusual pharmacological properties of compounds 
containing the 1,2-diphenylethylamine core have been studied 
since 1940 (see, for example, Dodds et al., 1945). The 
structurally simple lefetamine, also known as (–)-SPA, an 
obsolete — and internationally controlled — analgesic with 
some stimulant properties investigated in Japan in the early 
1960s and with limited medical use in Italy (Santenol) (see 
Janiri et al., 1989), also contains this structural core. From a 
historical point of view, the development of MT-45 was based 
on structural analogies to the experimental antipsychotic 
perathiepine and the analgesic-stimulant lefetamine. 
Interestingly, four substances related to MT-45 have recently 
emerged in the EU as ‘new psychoactive substances’: 
diphenidine (20), methoxphenidine (21), NEDPA (22) and 
NPDPA (23) also contain the 1,2-diphenylethylamine moiety. 
The pharmacology of the former two is, however, different: 
(20)  1-(1,2-diphenylethyl)piperidine
(21)  1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine
(22)  N-ethyl-1,2-diphenylethylamine
(23)  N-isopropyl-1,2-diphenylethylamine 
their anaesthetic and ‘dissociative’ effects are similar to 
ketamine and are due to their non-competitive antagonism at 
the NMDA (N-methyl-D-aspartate) receptor complex (Berger 
et al., 2009; Wallach et al., 2014).
During a research programme starting in the early 1970s and 
spanning two decades, scientists at Dainippon 
Pharmaceutical Company prepared and investigated over 100 
N-(1,2-diphenylethyl)piperazine derivatives (Umemoto et al, 
1972; Natsuka et al., 1975, 1978, 1987, 1999). Among the first 
series of compounds, MT-45 stood out as a promising 
analgesic agent comparable to morphine (Natsuka et al., 
1975).
The analgesic activity of racemic MT-45 as well as the 
individual (S)- and (R)-MT-45 stereoisomers were compared 
to morphine and lefetamine and used methods according to 
the standards of the day with rodents as experimental 
animals. Specifically, thermal pain was induced by heat light 
radiation onto the tail of the animal (D’Amour-Smith or tail-flick 
method), mechanical pain was induced by pressing the tail of 
the animal (modified Haffner test), chemical pain was induced 
by administering phenylquinone or acetic acid 
intraperitoneally to the animal (writhing method), while 
electrical pain was induced by applying electrical stimuli by 
sub-cutaneous electrodes inserted in the base of the tail of 
the animal. The analgesic activity of the compounds is 
expressed as weight-based ED
50
 values (24) calculated from 
dose-response curves (for details, see Nakamura and Shimizu, 
1976). The results are summarised in Table 1.
As can be seen in Table 1, the analgesic activity of racemic 
MT-45 was comparable to morphine against all noxious stimuli 
except, perhaps, against chemically induced pain. Comparing 
the ED
50
 values shown in Table 1, it is also evident that the 
analgesic activity of MT-45 resides in the dextrorotatory (S) 
isomer. For example, the respective subcutaneous ED
50
 values 
of (S)- and (R)-MT-45 are 1.92 and 50.7 mg/kg in the mouse 
thermal pain test. Because of its higher molecular mass (25), 
racemic MT-45 is somewhat more active than morphine on a 
molar basis in some of the assays.
It is notable that upon subcutaneous injection the analgesic 
activity of the (S) enantiomer of MT-45, even on weight-based 
(24)  ED
50
, or median effective dose, is the dose causing 50 % of the maximum or 
an arbitrary but well-defined effect for the measured biological effect of 
interest.
(25)  Because of its higher molecular weight, MT-45 (348.54 for the free base 
and 421.45 for the dihydrochloride salt) is more active than morphine 
(285.34 for the free base and 321.80 for the hydrochloride salt) in some 
assays when using molar ED
50
 values instead of the weight-based values 
given in Table 1. For example, the respective molar ED
50
 values for 
subcutaneously administered morphine and racemic MT-45 are 7.4 and 
7.3 mmol/kg thermal (tail-flick) test, 7.5 and 5.1 mmol/kg in the mechanical 
(Haffner) test, and 1.8 and 5.3 mmol/kg in the chemical (writhing) test in 
the mouse.
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terms, is higher than that of morphine in most animal tests. 
Upon oral administration, however, morphine appears to be 
more active in some of the assays shown in Table 1.
Lefetamine was less active than MT-45 as an analgesic in all 
tests in both rodent species.
The relationship between the analgesic activity in the mouse 
and the opioid receptor binding in vitro using rat brain 
homogenate preparations was studied for MT-45 and its 
individual enantiomers; morphine and lefetamine were used 
as comparative standards (Fujimura et al., 1978; Imai, 1982; 
Nozaki et al., 1983; see also Nozaki et al., 1989). To evaluate 
the effect of the substances on peripheral opioid receptors, 
inhibition of electrically induced contractions of the 
longitudinal muscle of guinea pig isolated ileum (27) was also 
determined. Receptor affinities of the test compounds were 
characterised by estimating the binding inhibition (IC
50
 
values (28)) of the specific radioligand to the receptor 
preparation. The radioligands used were: [3H]naloxone 
(preference to MOP receptors), [3H]dihydromorphine 
(preference to MOP receptors), DADLE ([3H](D-Ala2,D-Leu5]
(26)  Thermal pain was induced by heat light radiation onto the tail of the animal 
(D’Amour-Smith or tail-flick method), mechanical pain was induced by 
pressing the tail of the animal (modified Haffner test), chemical pain was 
induced by administering phenylquinone or acetic acid intraperitoneally to 
the animal (writhing method), while electrical pain was induced by applying 
electrical stimuli by subcutaneous electrodes inserted in the base of the tail 
of the animal.
(27)  The guinea pig ileum is now known to possess multiple opioid receptor types, 
namely MOP and KOP receptors, with few or no DOP receptors.
(28)  IC
50
 is the concentration of the test compound required to displace 50 % of 
the radiolabelled ligand from the receptor.
enkephalin; DOP receptor specific), and EKC ([3H]
ethylketocyclazocine; KOP receptor specific). The results are 
shown in Tables 2 and 3 (29).
A comparison of the in vivo analgesic activity data shown in 
Table 2 indicates that the racemate and the (S)-isomer of 
MT-45 are more potent than morphine. The (R)-isomer is 
less active than morphine though its analgesic effect is 
comparable to that of lefetamine. In the isolated guinea pig 
ileum assay in situ, the (S)-isomer of MT-45 displayed high 
activity although it was still 2.6-fold less active than 
morphine in inhibiting electrically induced contractions in 
this experimental setup. Similar to morphine, MT-45 and 
both its isomers displayed strong antinociception when 
injected directly into the brain (i.e. by the 
intracerebroventricular route), thus a central mode of 
analgesic action is evident.
(29)  Since discrepancies in some of the receptor affinity values on morphine-
competition assays in publications from this group have been noted, 
relevant data were taken from the most recent publication (Nozaki et al., 
1983).
TABLE 1
Analgesic activity (ED
50
 values in mg/kg) of morphine hydrochloride and MT-45 and its stereoisomers, all as dihydrochlorides, 
and lefetamine hydrochloride upon subcutaneous (s.c.) or oral administration (male animals; n = 18–54) (Natsuka et al., 1975; 
Nakamura and Shimizu, 1976; Imai, 1982) (39)
Drug
Mice Rats
Thermal Mechanical Electrical Chemical Thermal Mechanical
Morphine  s.c. 
s.c. 
oral
2.39
29.4
2.41
15.4
1.22
7.70
0.58 (a)
0.47 (b)
4.20 (a)
3.79
41.0
1.17
32.0
Rac. MT-45  s.c. 
s.c. 
oral
3.09
20.9
2.15
11.9
1.54
30.8
2.24 (a)
0.64 (b)
12.5 (a)
6.62
29.5
0.73
36.4
(S)-MT-45  s.c. 
s.c. 
oral
1.92
20.9
1.09
5.51
0.91
14.8
1.97 (a)
0.40 (b)
10.6 (a)
5.39
No data
0.73
26.0
(R)-MT-45  s.c. 
s.c. 
oral
50.7
No data
27.4
No data
38.3
41.0
36.0 (a)
1.0 (b)
73.3 (a)
≥75
No data
45.0
No data
Lefetamine  s.c. 
s.c. 
oral
46.6
>240
19.4
68.6
17.9
>100
3.86 (a)
6.0 (b)
52.3 (a)
36.9
>240
42.0
>240
(a) Phenylquinone-induced pain (Natsuka et al., 1975; Nakamura and Shimizu, 1976).
(b) Acetic acid-induced pain (Kobayashi, 1991).
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TABLE 2
Analgesic activity in mice and inhibition of electrically 
induced contraction of guinea pig ileum preparation by 
MT-45 and its stereoisomers, all as dihydrochlorides, 
morphine hydrochloride and lefetamine hydrochloride 
(Fujimura et al., 1978; Imai, 1982; Nozaki et al, 1983)
Drug
Analgesic activity, ED
50
Guinea pig ileum 
contraction, IC
50
s.c.
mg/kg
i.c.v.
μg/kg
nM
Morphine 5.9 0.40 4.8
rac. MT-45 1.7 0.12 15.3
(S)-MT-45  4.4 0.35 12.7
(R)-MT-45 30.0 2.00 107
Lefetamine 19.0 3.20 138
Abbreviations: s.c.: subcutaneous injection; i.c.v.: intracerebroventricular 
injection.
TABLE 3
Affinities of morphine hydrochloride, MT-45 and its 
stereoisomers, all as dihydrochlorides, and lefetamine 
hydrochloride to binding sites of various tritiated ligands in 
rat brain homogenates (Fujimura et al., 1978; Imai, 1982; 
Nozaki et al, 1983)
Drug
IC
50
, nM
DHM NLX DADLE EKC
Morphine 4.6 5.5 78.6 242
rac. MT-45 644 743 156 176
(S)-MT-45 736 143 70.6 78.0
(R)-MT-45 1610 1210 614 791
Lefetamine 3082 3685 1110 4022
Abbreviations: DHM: [3H
2
]dihydromorphine; NLX: [3H]naloxone; DADLE: [3H]
(D-Ala2,D-Leu5]enkephalin; EKC: [3H]ethylketocyclazocine.
Data on competitive binding to purified receptor preparations 
reveal some receptor type selectivity (Table 3). The (S) isomer 
and the racemate of MT-45 are poor inhibitors of the binding 
of the tritiated dihydromorphine and naloxone probes 
indicating low affinity to MOP receptors. However, (S)-MT-45 
efficiently competes with the DOP-selective tritiated 
enkephalin analogue probe DADLE and is even more efficient 
in inhibiting the binding of the KOP-selective [3H]
ethylketocyclazine ligand with an IC
50
 value three-fold lower 
than that of morphine. Accordingly, this isomer is a preferential 
DOP and KOP receptor ligand. According to data shown in 
Table 3, the receptor selectivity of (R)-MT-45 is lower than that 
of its enantiomer, though a relatively high affinity to MOP 
receptors is retained.
In a separate study using different receptor preparations and 
[3H]diprenorphine as radioligand, the IC
50
 values for the MOP 
receptor were 0.17 µM and 11 µM for morphine and MT-45, 
respectively, while for the KOP receptor the IC
50
 values were 
0.42 µM and 16 µM for morphine and MT-45, respectively 
(Kobayashi, 1991).
Receptor binding experiments conducted in the presence or 
absence of Na+ shed light on the functional nature of receptor 
interaction and indicated that, similar to morphine, racemic 
MT-45 and (S)-MT-45 are opioid receptor agonists: the 
‘sodium index’ (30) for morphine, racemic MT-45, (S)-MT-45, 
(R)-MT-45 and naloxone was 26, 5, 6, 1 and 1, respectively 
(Fujimura et al., 1978; Imai, 1982).
Molecular modelling studies attempted to interpret the 
structural and conformational requirements responsible for 
the unique analgesic activity and receptor selectivity of the 
enantiomers of MT-45 and some of its analogues, lefetamine 
and morphine (Nozaki et al., 1989; Kobayashi, 1991).
The above experimental results indicate that MT-45 is an 
opioid receptor agonist and its morphine-like properties in 
vitro reside in the (S) enantiomer. The mode of analgesic 
action of the individual enantiomers and the racemic mixture, 
however, appears to be complex (31). It is notable that the 
(S)-isomer shows binding preference to DOP and KOP 
receptors. Interactions at an allosteric site that could 
contribute to the analgesic activity of the racemic mixture of 
MT-45 have also been suggested (32). Since the metabolism of 
MT-45 has not been studied, the potential contribution of 
metabolites, such as ring-hydroxylated derivatives, to the 
analgesic activity — or to the toxicity — of the substance is 
not known. (The analgesic activity and receptor binding of 
related synthetic phenols, which in theory could be formed in 
vivo by ring-hydroxylation of MT-45, has been studied; see 
Section A2 Pharmacokinetics above and paragraph below.)
Among the 1-substituted-4-(1,2-diphenylethyl)piperazine 
derivatives disclosed in a series of publications by Dainippon 
Pharmaceutical company, several compounds had equal or 
higher analgesic activity than MT-45. For example, 
replacement of the cyclohexane ring of MT-45 by larger (e.g. 
cycloheptane or cyclooctane) rings affords substances with 
strong analgesic activity. Notable also are certain phenol and 
(30)  The ability of Na+ to decrease the potency of opioid receptor agonists to 
opioid receptors with negligible effect on the potency of antagonist can be 
used to differentiate agonists from antagonists in simple binding 
experiments. Thus, for opioid receptor agonists the ‘sodium index‘, that is the 
ratio of IC
50
 values determined in the presence and in the absence of Na+, is 
larger than 1 (for a recent review on this allosteric phenomenon, see Katritch 
et al., 2014).
(31)  Several lines of evidence indicate that co-administration of MOP and DOP 
receptor agonists can result in synergistic analgesic effects (Ananthan, 
2006), while KOP receptor activation antagonises the analgesic activity of 
MOP receptor agonists (Pan, 1998).
(32)  It could be of relevance that a study by Matsuno et al. (1998) revealed that 
the (R)-MT-45 interacts with sigma receptors, which are known to modulate 
opioid analgesia.
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methoxy derivatives (33,34) (Nishimura et al., 1978; Natsuka et 
al., 1987, 1999; Kobayashi, 1991). Some analogues containing 
a substituted-phenyl group in place of the cyclohexyl group of 
MT-45 are 20 to 100 times more potent analgesics than 
morphine in animal assays (Natsuka et al., 1987). A further 
potent analogue is AD-1211 (35), which produces analgesia 
through a central mechanism but lacks respiration inhibition 
(Nakamura et al., 1985).
Respiratory depression, which is one of the most prominent 
adverse effects of MOP receptor agonists, of racemic MT-45, 
of its pure enantiomers and of morphine was examined in 
rabbits upon intravenous administration (Nakamura and 
Shimizu, 1976). At the 1 mg/kg dose, racemic MT-45 and 
(S)-MT-45 depressed respiration by 59 % and 57 %, 
respectively; the (R) enantiomer failed to cause any 
respiratory depression even at 5 mg/kg. In comparison, a dose 
of 3 mg/kg morphine depressed respiration by 63 %. These 
results suggest that for racemic MT-45 the acute toxicity risk 
due to respiratory depression is at least as high as for 
morphine (36).
The effects of racemic MT-45, its pure enantiomers and 
morphine on gastrointestinal motility were compared using 
the charcoal meal test in mice (Nakamura and Shimizu, 1976). 
At 3 mg/kg and 10 mg/kg subcutaneous doses, both racemic 
MT-45 and (S)-MT-45 reduced gut propulsion dose-
dependently but their potency was somewhat weaker than 
that of morphine at the same dosages. The (R) isomer of 
MT-45 was about tenfold less potent than the (S) isomer.
The effect on pupil size of subcutaneously administered 
MT-45 and its isomers was studied in mice and rabbits 
(Nakamura and Shimizu, 1976). In the mouse the mydriatic 
activity of racemic MT-45 was higher than that of morphine at 
the equal 10 mg/kg dose; at the 3 mg/kg dose the synthetic 
drug was somewhat less effective than morphine in increasing 
pupil diameter. However, the (S) isomer of MT-45 and 
morphine appeared to be equally active at the 3 mg/kg dose. 
The (R) isomer had negligible effect on pupil size even at the 
30 mg/kg dose. In the rabbit, miotic response was observed 
for morphine at 10 mg/kg but none of the MT-45 preparations 
had any effect on pupil size at this dose.
(33)  3-[2-(4-Cyclohexylpiperazin-1-yl)-2-phenylethyl]phenol and 1-cyclohexyl-4-
[2-(3-methoxyphenyl)-1-phenylethyl]piperazine, respectively.
(34)  The para-hydroxy analogue, that is ‘4-[2-(4-cyclohexylpiperazin-1-yl)-2-
phenylethyl]phenol’, which is less active than MT-45 (Natsuka et al., 1978), 
has been advertised on the Internet: www.lookchem.com/cas-633/63384-
27-0.html; www.molbase.com/en/cas-63384-27-0.html (August 2014).
(35)  3-{2-[4-(3-methylbut-2-en-1-yl)piperazin-1-yl]-2-phenylethyl}phenol
(36)  The toxic symptoms, including respiratory depression, observed in non-fatal 
human overdose cases related to MT-45 use could successfully be treated 
with naloxone administration (Helander et al., 2014; see also Section D1.2).
In the mouse, the Straub-tail indexes (37) for racemic MT-45, 
its (S) isomer and morphine were estimated to be 7.34, 30 
and 33.1, respectively, suggesting the involvement of the 
opioid system in the pharmacology of the synthetic 
piperazine derivatives (Nishimura et al.,1976; see also 
Natsuka et al., 1987).
The local anaesthetic activity of MT-45 and both of its 
isomers was investigated using the corneal reflex method in 
guinea pigs with morphine and procaine as comparative 
standards (Nakamura and Shimizu, 1976). The local 
anaesthetic activity of (R)-MT-45 was the highest of the test 
compounds with a mean effective concentration of 0.03 %. 
For racemic MT-45, (S)-MT-45, morphine and procaine the 
mean effective concentration values were 0.092, 0.16, 2.0 
and 0.27 %, respectively. (Note that it is (S)-MT-45 that is 
mostly responsible for the analgesic activity of the drug, 
although it is assumed that the (R) enantiomer also 
contributes to the overall biological activity of the racemic 
mixture; see Tables 1 and 2.)
The effect of MT-45, its isomers and morphine on body 
temperature after subcutaneous injection of 3 or 10 mg/kg 
doses were studied by recording changes in rectal 
temperature of separately kept Wistar rats (Nakamura and 
Shimizu, 1976). While (R)-MT-45 had negligible effects at 
these doses, 10 mg/kg of racemic MT-45 transiently increased 
the rectal temperature by 1.02 oC, though this hyperthermia 
was much milder than that of morphine at the same dose; the 
effect of (S)-MT-45 on body temperature was comparable to 
that of the racemic drug.
While morphine at 10 mg/kg subcutaneous administration 
caused a remarkable change (~136 % increase) in plasma 
glucose level in rabbits compared to untreated animals, the 
hyperglycemic activity MT-45 was much weaker (~40 % 
increase) at this dose (Nakamura and Shimizu, 1976).
Matsuno et al. (1998) examined the involvement of sigma 
receptors (38) in the psycho-pharmacological activity of 
MT-45. It was found that intraperitoneally administered 
(R)-MT-45 (39) produced significant memory impairment in the 
(37)  The ‘Straub-tail index’ is defined as the ratio of the intravenous LD
50
 value 
and the Straub tail ED
50
 value, where the Straub tail ED
50
 is defined as the 
dose, injected intravenously through the tail vein of the animal, producing 
Straub-reaction (rigid tail held upright and tending to curling over the back of 
the animal in an S-shaped curve) in 50 % of the treated animals. The 
Straub-index was once used to assess dependence liability of drugs, 
including narcotics.
(38)  Initially, sigma receptors were proposed to be as a subtype of opioid receptor 
but they are no longer considered to be opioid receptors. Nevertheless, 
sigma receptors can influence opioid actions, including analgesia. The s
1
 and 
s
2
 sigma receptor subtypes have been well characterised. Receptor subtype 
s
1
 could be a potential target for the treatment of a host of neuropsychiatric 
disorders, such as schizophrenia, depression and cognitive disorders, as well 
as brain ischemia and drug dependence.
(39)  The substance was codenamed ‘CDEP’ by the authors of this study.
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mouse passive avoidance learning performance test. This 
memory impairment could be alleviated by subcutaneous 
administration of sigma receptor agonists, such as 
(+)-N-allylnormetazocine, suggesting that the observed 
memory impairment is due to the antagonist effect of (R)-
MT-45 at sigma receptors and thus unrelated to opioid 
receptors (see Pan, 1998). A receptor binding study, using 
guinea pig brain membrane preparation and [3H]pentazocine 
as radioligand, revealed that (R)-MT-45 possessed high 
affinities for both s
1
 and s
2
 receptor subtypes with IC
50
 values 
of 1.4 nM and 1.8 nM, respectively.
In an in vivo screening programme conducted at the National 
Cancer Institute (USA), MT-45, codenamed NSC299236, was 
found inactive in two P388 leukaemia mouse models at 25 or 
50 mg/kg intraperitoneally injected doses (NCBI, 2014).
No studies were identified that have examined the 
pharmacology of MT-45 or its close analogues in humans. For 
the acute physiological and psychological effects noted in 
users of MT-45, see Section D1.2.
I A3. Psychological and behavioural effects
As described in Section A2, animal studies only characterised 
the narcotic-analgesic effects of MT-45. There is limited 
information on the behavioural effects of MT-45 in animals (for 
dependence liability studies, see Section B1; for different toxic 
symptoms observed for the enantiomers administered at 
non-lethal doses, see Section D1.1).
There are no published formal studies assessing the 
psychological and/or behavioural effects of MT-45 in humans. 
Limited information available on user websites indicates that 
the effects of MT-45 resemble those of opioids. (For effects 
described in selected users’ self-reports, see Section D1.2.1.)
I A4. Legitimate uses of the product 
No information was provided by any Member State, Turkey and 
Norway indicating industrial, agrochemical, cosmetic, 
veterinary or human medical use. The legitimate use of MT-45 
is currently restricted to scientific research, if any, and as an 
analytical reference standard.
There is no information that MT-45 is currently used in the 
manufacture of a medicinal product in the European Union. 
However, in the absence of a European Union database on the 
synthetic routes of all medicinal products this information 
cannot be verified. There is no marketing authorisation 
(existing, ongoing or suspended) for MT-45 in the European 
Union or in the Member States (EMCDDA and Europol, 2014). 
Literature searches have indicated that the 
1-(1,2-diphenylethyl)piperazine core structure present in 
MT-45 is a unique and rarely used template in medicinal 
chemistry (40).
As mentioned in Section A2, several 1,2-diphenylethylamine 
derivatives structurally related to MT-45 have been 
investigated but none of them was marketed as a medicine. 
Close analogues of 1-(1,2-diphenylethyl)piperazines, such as 
the corresponding cathinone-like aminoketones (also called 
‘desyl-piperazines’ or, formally, 1,2-diphenyl-2-(piperazin-1-yl)-
ethanones) and ephedrine-like aminoalcohols (formally 
1,2-diphenyl-2-(piperazin-1-yl)ethanols) have been described 
(Gruenman and Hoffer, 1967; Shimokawa et al., 1979; Li et al., 
2006).
I  Section B. Dependence and abuse potential
I B1. Animal in vivo and in vitro data
The dependence liability of racemic MT-45 and (S)-MT-45 was 
assessed in rodents (Nishimura et al.,1976; see also: Natsuka 
et al., 1987). Nalorphine-treatment of mice that had received 
repeated doses of the test substances precipitated jumping 
behaviour and other withdrawal signs similar to those noted 
for morphine in the same assay. Furthermore, MT-45 
substituted for morphine in morphine-dependent rats. To 
assess dependence liability, Nishimura et al. (1976) 
determined the Straub-index in the mouse (see Section A2 for 
discussion) for racemic MT-45, (S)-MT-45 and morphine as 
7.34, 30 and 33.1, respectively. Note, however, that the 
Straub-tail response is now known to be an inadequate 
method for dependence assessment. Nevertheless, these 
data indicate that (S)-MT-45 has morphine-like 
pharmacological properties.
No animal self-administration studies appear to have been 
published. Tolerance, cross-tolerance or sensitisation studies 
are also lacking.
(40)  A literature search in SciFinder® (CAS, American Chemical Society) using the 
molecular structure of MT-45 retrieved a patent (Haggerty et al., 2012) listing 
MT-45, by its systematic name, among hundreds of potential adjuvants with 
possible use in cancer therapy. Furthermore, the search retrieved not only 
publications on the queried substance but also two irrelevant inorganic 
chemistry publications that apparently use ‘IC6’ as an acronym for some 
other chemical.
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I B2. Human data
No studies were identified that have examined the 
dependence and/or abuse potential of MT-45 in humans. 
There are no user reports or published cases in the scientific 
or grey literature describing the potential for dependence or 
the abuse potential of MT-45. Additionally, there have been no 
formal studies investigating the dependence and/or abuse 
potential of MT-45 in humans. 
We are not aware of any reports from local, regional or national 
drug treatment agencies relating to MT-45 dependence.
Some self-reported user experiences (‘trip reports’) on user 
websites suggest tolerance and describe withdrawal-like 
symptoms as ‘minor but still unpleasant’, ‘hot and cold, dry 
retching’ and ‘my pupils were huge’ (Bluelight, 2014a).
I Section C. Prevalence of use
I  Information from seizures, collected and biological samples
MT-45 was first detected in a seizure by customs authorities in 
Sweden on 15 October 2013, with formal notification to the 
EU Early Warning System on 5 December 2013. Subsequently, 
two more European countries, Belgium and Germany, 
reported the detection of MT-45 to the EU Early Warning 
System (41) in one or more seizures, collected samples or 
intoxication cases. The details of the seizures, indicating year, 
number, amount and seizing authority by these member 
states are listed in Table 4. MT-45 has mostly been 
encountered in white or off-white powder form. In three of the 
powder samples another ‘new psychoactive substance’ was 
also detected. MT-45 was also found in two herbal smoking 
mixtures along with a synthetic cannabinoid. No detection of 
MT-45 has been reported by the other Member States, Turkey 
and Norway.
(41)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, 
etc.) and/or other specimens (tissues, hair, etc.).
TABLE 4
Details of seizures and collected samples of MT-45 reported 
to the EMCDDA and Europol
Country Amount and details of the seizure/collected sample
Belgium
2014 Detected in a powder sample obtained from a user 
who purchased it from an Internet shop and had it 
tested by a ‘pill testing’ service. The sample also 
contained methylone.
Germany
2013 One seizure by the police of a ‘light brown chunky 
substance’ (11.3 g) containing MT-45, heroin base, 
caffeine, paracetamol, and sorbitol.
2014 One seizure by the police of white powder (250.49 g) 
containing MT-45 of 95 % purity.
Sweden
2013 One seizure of white powder (49.9 g) by customs, four 
seizures (0.51, 1.3, 2.12 and 4.08 g; all white powders) 
by police.
2014 Twenty-nine seizures (ranging from 0.1–9 g) as white 
powders; one of these samples contained 6-APDB, 
another one alpha-PBP, both synthetic stimulant. Two 
further seizures (0.55 and 0.99 g) of herbal material 
contained MT-45 along with a synthetic cannabinoid 
(AB-FUBINACA or AKB48). With the exception of one 
seizure that was made by customs authorities, all 
seizures were made by the police.
The drug has also been encountered in Japan (Uchiyama et 
al., 2014) and in the USA (42).
I Availability from Internet retailers
According to Internet searches for ‘MT-45’ conducted several 
times from early 2014 to August 2014, the family of 
‘piperazine-opioids’ was discussed as early as October 2006 
with a short list of scientific publications on MT-45 (Bluelight, 
2014b). A Wikipedia entry was created in March 2011 
(Wikipedia, 2014). Experience reports followed from 2012 
(Bluelight, 2014a; Flashback, 2014; Shroomery, 2014). 
According to Google Trends (43), the first peak of the Google-
defined relative search frequency for ‘MT-45’ emerged in 
September 2012.
According to Swedish chat forums on psychoactive 
substances, MT-45 was used in Sweden in May 2013 
(Helander et al., 2014).
For the purpose of the EMCDDA–Europol Joint Report on 
MT-45, a structured search of the Internet was conducted in 
(42)  ‘HSI seizes websites selling potentially deadly illegal narcotics’, news release 
dated 11 April (www.ice.gov/news/releases/1404/140411buffalo.htm). 
(43)  www.google.com/trends 
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June 2014 for Internet suppliers (which typically appear to be 
manufacturers and/or wholesalers) and retailers selling 
MT-45 (44) (Google, 2014). Twelve sites that appear to be 
based either within the EU, Canada, China and India were 
identified. Five of the sites only provided quantities and prices 
for MT-45 on application. The remaining seven sites listed 
quantities and prices. Briefly: the minimum quantity offered 
was 1 g (n=2 sites) with a mean price of EUR 33.25 
(EUR 22.16–44.34); the maximum quantity offered was 
5 000 g (n=1 site) with a price of EUR 12,900. Most of the 
seven sites offered quantities ranging from 10–1 000 g. The 
mean price for 10 g (n=5 sites) was EUR 178.11 (EUR 129–
311.01); the mean price for 100 g (n=5 sites) was EUR 778.37 
(EUR 498.00–1 107.90); the mean price for 1 000 g (n=5 
sites) was EUR 3 041.02 (EUR 2 363.52–3 914.58). On these 
sites MT-45 was typically sold as a ‘research chemical’. 
Repeating the search in August 2014 gave similar results. For 
example, 10 g, 100 g or 1 kg of MT-45 were offered for 
USD 180, 700 or 3 200, respectively (45); another supplier 
offered 1 kg of MT-45 for USD 6 716 (46).
An Internet snapshot survey undertaken in English during 
June 2014 identified 17 sites selling MT-45 (16 were common 
to both google.co.uk and google.com; one identified on google.
com only). The country of origin was identifiable from the 
Internet site as follows: China eight; Canada two; Germany 
one; India one; and Sweden one; it was not possible to identify 
the country of origin for four Internet sites. Nine Internet sites 
had no information directly available on cost and this was only 
available to registered users and/or on request. Of the eight 
Internet sites where information was available on cost, six 
were selling in dollars (assumed to be US dollars, although not 
explicitly stated), one in Euros and one in Swedish Krona. 
MT-45 was for sale in amounts ranging from 500 mg to 5 kg. 
The mean price of MT-45 decreased with increasing purchase 
amounts from USD 57.6 ± 19.37 per gram for a 1 g purchase 
to USD 3.36 ± 1.83 per gram for a 1 kg purchase (personal 
communication to the EMCDDA from David Wood) (47).
In three of the non-fatal intoxications reported by Sweden the 
source of the MT-45 was reported to be the Internet. In the 
remaining seven cases, the source was unknown (see Table 6 
in Section D1.2).
(44)  Using the standardised EMCDDA methodology for monitoring Internet sales 
of new psychoactive substances. Briefly, google.co.uk was searched using 
the term ‘buy “MT-45”’ and the first 100 search results were reviewed. 
Further details on the methodology are available from the EMCDDA on 
request.
(45)  www.lsresearchchems.com/views.asp?hw_id=155 
(46)  www.molbase.com/en/cas-41537-67-1.html 
(47)  These data has now been published, see: Siddiqi, S., Verney, C.H., Dargan, P., 
Wood, D.M. (2014), ‘Understanding the availability, prevalence of use, desired 
effects, acute toxicity and dependence potential of the novel opioid MT-45’, 
Clin Toxicol (Phila) 2014; In press. 
I Prevalence of use
There are currently no coordinated national or European 
surveys on the prevalence of use of MT-45 in the general 
population or in targeted populations. Further, neither the 
European School Survey Project on Alcohol and Other Drugs 
(ESPAD) nor other school/college/university surveys have 
investigated or reported on MT-45 use.
I Section D. Health risks
I D1. Acute health effects
D1.1. Animal data
The acute toxicity of MT-45 to rodents was extensively studied 
by the company developing it. The toxicity data are shown in 
Table 5 and are expressed as LD
50
 values, that is the dosage 
causing death in 50 % of the exposed animals. Mortality was 
monitored for seven days after the administration of a single 
dose of the drug. In summary, by the oral and subcutaneous 
route, the (S) isomer was more toxic than racemic MT-45, 
though no such difference could be observed by the 
intravenous route. It is also evident that MT-45 preparations, 
regardless of stereochemical composition, are more toxic to 
rodents than morphine. On weight basis in the mouse, for 
example, racemic MT-45 was over fourfold more toxic than 
morphine by the oral route; by the intravenous route the 
toxicity difference was larger: MT-45 was about elevenfold 
more toxic than morphine. During the toxicity study, it was 
also noted that animals receiving toxic doses of racemic 
MT-45 and its analgesically more active (S) isomer died with 
symptoms of laboured breathing (dyspnoea), severe sedation 
and muscle rigidity. Interestingly, in lower, sub-lethal doses the 
racemic mixture and the (S) isomer of MT-45 caused 
excitation, while the (R) isomer caused sedation. This 
remarkable observation in vivo indicates different modes of 
action for the two stereoisomers that is also reflected by in 
vitro studies (Section A2). 
Apart from respiratory depression (see above), there is 
insufficient information available to determine the clinical 
features in animals of acute toxicity associated with MT-45.
No data are available on the chronic toxicity of MT-45.
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The RTECS Number for the dihydrochloride of MT-45 is  
TL3486500 (49).
D1.2. Human data
No clinical studies were identified that have systematically 
examined the toxicity or adverse effects of MT-45 in humans. 
The sub-sections that follow summarise selected, though 
typical, user reports and reports from Sweden on 18 non 
fatal-intoxications requiring emergency treatment following 
MT-45 use (50). The clinical findings reported by Sweden on 28 
deaths are also presented.
D1.2.1. User reports
There are few user reports discussing the subjective effects 
of MT-45. The section below is mainly based on discussions 
originating from Internet drug forums and related websites 
(hereafter ‘user websites’) and includes self-reports. As such 
it is important to note that it is not possible to confirm the 
identity, the purity, the dose/amount, etc., of the specific 
substance(s) used. Analyses of new psychoactive 
substances or products containing them that are sold on the 
drug market have shown that the composition can differ from 
that claimed by the retailer, and can vary over geographical 
areas and time. Furthermore, the users’ physical 
(48)  For comparison, LD50 values of morphine (rat, i.v.) range between 64–223 
mg/kg depending upon which salt of the drug and which strain of rat are 
used (Strandberg et al., 2006; Niemegeers et al., 1976. Finnegan et al., 
1948).
(49)  RTECS stands for Registry of Toxic Effects of Chemical Substances, which is 
a compendium of toxicity data extracted from the scientific literature. The 
database was originally developed by The US National Institute of 
Occupational Safety and Health (www.cdc.gov/niosh/rtecs/RTECSaccess.
html) but it is now maintained by Accelrys-BIOVIA of Dassault Systèmes.
(50)  During data collection for the risk assessment, the Swedish national focal 
point reported a total of 20 non-fatal intoxications associated with MT-45 
use for the period from November 2013 up to August 2014 (see Table 6). 
Subsequently, Helander et al. (2014) reported the details of clinical findings 
of nine non-fatal intoxications all of which had been included in the report 
from the Swedish national focal point.
characteristics and health status are rarely reported. In 
addition, the information on user websites should be 
regarded as illustrative only and not taken as representative 
of users of MT-45 in general. Consequently, these reports 
should be interpreted with caution.
Some users reported feeling high, a ‘decent buzz’ followed 
by sedation; and some of them add qualifying comments, 
such as ‘feels good like an opi but lacking euphoria or that 
good deep opi feeling’ or ‘nice calm opiate undertones’. 
Typical opioid effects such as itching were noted by several 
users and nausea appears to be a common feature. Several 
users reported that they experienced analgesia whilst taking 
MT-45. One user reported commencing MT-45 use ‘as I was 
going into heroin withdrawal last week’, suggesting self-
medication with MT-45 to ease opiate withdrawal symptoms. 
This was echoed by another user, who noted, ‘maybe good to 
avoid w/d but not much recreation in my opinion’. Three 
users suggested the effects of MT-45 were similar to those 
of methadone, one to the synthetic opioid AH-7921, one to 
codeine and one to oxycodone. No serious adverse events 
were mentioned in these reports (Bluelight, 2014a; 
Chems’R’us, 2014; Shroomery, 2014). Representative 
quotations follow.
Bluelight
The first user report appeared in September 2012 on this 
user website (Bluelight, 2014). One user who had previously 
experimented with inhaling the vaporised base of MT-45 
‘tried 80 mg of MT-45 salt solution rectally. I expected this to 
be a full dose and was surprised to find “maybe threshold” 
effects over the following hour. This was supplemented by 
30 mg converted to base and vaped, which gave full effects’. 
Another user compared the effect of a total of 75 mg with 
redosing (10 mg + 15 mg + 15 mg + 35 mg doses at one 
hour intervals) on one occasion to the effects of same 
amount taken in a single dose on an empty stomach. In the 
former case, the effects were described as ‘subtle night but 
was quite decent, was itchy and pretty warm. Definite 
TABLE 5
Acute toxicity data (LD
50
 values in mg/kg) of morphine hydrochloride, MT-45 and its stereoisomers, all as dihydrochlorides, and 
lefetamine hydrochloride upon subcutaneous (s.c.), intravenous (i.v.) or oral administration (male animals; n = 20–50) 
(Nakamura and Shimizu, 1976; Nishimura et al., 1976)
Drug
Mice Rats
oral s.c. i.v. oral s.c. i.v.
Morphine 1402 560 204 335 Not tested Not tested (61)
Rac. MT-45 329 743 17.8 150 136 7.8
(S)-MT-45 274 320 18.5 Not tested Not tested 8.0
(R)-MT-45 250 Not tested 17.9 288 97.7 12.9
Lefetamine 176 104 32.6 ~300 148 Not tested
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opiate.’ In the latter case, two hours after the bolus intake ‘I 
was way too high, profusely sweating and vomited. Felt 
reminiscent of Kratom and Codeine/Promethazine’. An 
‘opioid-tolerant’ user compared the effect of 100 mg of 
MT-45 to 10–15 mg of methadone. This user ‘took 30 mg on 
one night and was hung over the next day feeling akin to 
how I feel the day after MDMA, something no opiate has 
done to me before’. A self-medicating user described ’35 mg 
very pure MT-45 Dihydrochloride taken in a capsule 
alongside with 250 mg of Chelated Magnesium and copious 
amount of bud [most likely Budweiser beer] …. All my back 
pain and arthritis pain disappeared’. A report described a 
‘high, very pleasant’ feeling after snorting about 20 mg of 
MT-45; ‘pupil constriction, dulled sensation to pain and a 
mild amount of euphoria’ were noticed. Another user wishing 
to relieve the symptoms of heroin withdrawal needed in total 
about 240 mg of MT-45, taken orally over the course 2.5 
hours, to feel the calming effect of the substance; for a 
lasting relief, additional amounts ‘whenever I felt the need … 
around 300–400 mg over 6 hours’ were ingested. The same 
report concluded: “for getting high — no so great …. For 
(minor) withdrawals — Amazing considering its availability 
and legality (grey area). Took away almost all symptoms’. 
The effects of a mixed intoxication with MT-45, cannabis 
and ketamine were also communicated by one opioid naive 
user as follows: ‘I weighed 45 mg of mt45, capped it and 
swallowed on an empty stomach and normal habitual 
cannabis consumption’; after 30 minutes, ‘I notice myself 
scratching my head …’; after 1.5 hours ‘seems equivalent to 
taking 10 mg hydrocodone, with maybe some tramadol like 
agonist/antagonist feelings’; after two hours, being ‘bored 
with opiate lazies … I shovel myself up 75 mg of racemic 
ketamine hcl for an IM injection … lower than normal khole 
because I am alone, and I expect it to be potentiated by the 
mt45’; about 15 minutes after injecting ketamine, ‘Bliss … 
My mind is completely free to wander. I feel like I am floating 
in the clouds .... I may have found my sweet spot for dosage. 
Right on the edge of K-Hole’; 3.5 hours after MT-45 intake ‘I 
seamlessly doze off to sleep’.
Flashback
The first report on this Swedish language user website about a 
user’s experience with MT-45 appeared in December 2013 
and described a total of 200 mg of MT-45 administered first 
nasally (10 mg) and sublingually (5 mg) (Flashback, 2014). 
Apart from the bad taste and smell, the first noticeable effect 
was the numbing of the mouth and the throat. Nasal re-dosing 
of 20 mg and 40 mg at 60 minutes and 110 minutes, 
respectively, after the first dose, resulted in strongly 
constricted pupils, and a relaxed but not euphoric feeling. 
Additional oral doses (2 x 60 mg as ‘bombing’) and one 
sublingual dose (35 mg) followed 3 and 3.5 hours after the 
first dose. 
Chems’R’us
Discussions of MT-45 started on this website in the ‘legal 
opioids’ category early in 2013 (Chems’R’us, 2014). One 
experience report described how, by rubbing over the gums 
(‘dabbing’) a few milligrams of powdery MT-45, the effects 
‘within 5 mins … kicked in. Very trippy, no warm opiate 
sensation’; 30 minutes later ‘sweaty palms and feet, little 
anxiety’ were noted. Another user commented later that a 
mixture of AH-7921 and MT-45 in a 1:1 ratio was as euphoric 
and addictive as oxycodone.
Shroomery
An experience report was posted in May 2014 on the effects 
of a ’76 mg capsule of MT-45 Dihydrochloride’ taken on an 
empty stomach by a person with ‘zero opiate tolerance’ 
(Shroomery, 2014). One hour after drug ingestion and a 
subsequent meal the effects described were ‘general sense 
of well-being, slightly stimulated’, ‘getting warm and sweaty 
palms and some itching’; these effects peaked half an hour 
later with some anxiety. At about two hours post-ingestion 
the user felt ‘woozy and dizzy’, was sweating and had to 
vomit. The effects started to fade four hours after drug 
intake with only ‘after effects’ being felt eight hours after 
ingestion. It was concluded: ‘The effects lasted VERY long. I 
would say similar to methadone? This is a great chemical. 
With no human research besides us guinea pigs, you have to 
wonder what receptors this stuff binds to and what it is 
actually doing.’
D.1.2.2. MT-45 associated acute toxicity 
The Swedish national focal point reported 46 serious adverse 
events (51) associated with MT-45 between November 2013 
and July 2014. Of the 46 cases, 18 were non-fatal 
intoxications (12 have been analytically confirmed) and 28 
were deaths. In one of these deaths MT-45 was detected in 
biological samples and the cause of death was reported as 
‘injury’.
Belgium notified that a user had reported to a pill-testing 
organization sedative effects due to the consumption of a 
powdery substance that, upon analytical examination, turned 
out to be a mixture of MT-45 and methylone.
(51)  Serious adverse event means any adverse event associated with the 
consumption of a new psychoactive substance in a human that: results in 
death; is life-threatening; requires hospitalisation; results in persistent or 
significant disability or incapacity; consists of a congenital anomaly or birth 
defect; or is an important medical event that may not be immediately 
life-threatening or result in death or hospitalisation but may jeopardise the 
patient or may require intervention to prevent one of the other outcomes 
listed above should also be considered serious. Examples of such events 
are intensive treatment in an emergency room; convulsions that do not 
result in hospitalisation; or development of substance dependency or 
substance abuse. This definition was adapted from the guidelines of ICH 
(1994).
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No non-fatal intoxications or deaths were reported by other EU 
Member States, Turkey and Norway.
Non-fatal cases reported by Sweden
There have been 12 cases where MT-45 was analytically 
confirmed in non-fatal intoxications associated with MT-45 as 
reported by the Swedish Poison Information Centre or 
National Laboratory of Forensic Chemistry (52). The cases 
occurred during 2013 (four cases) and 2014 (eight cases). All 
these cases were males aged between 17 and 37. The forensic 
and clinical results for these cases are summarised in Table 6.
A recent scientific publication by Helander et al. (2014) 
describes the details of analytical and clinical findings for nine 
of these 12 non-fatal intoxications. Key data are summarised 
in Table 7. Note that all these cases are also listed in Table 6.
Based on the reports on non-fatal intoxications, the clinical 
features of MT-45 overdose are opioid-like adverse symptoms 
typically including:
n  somnolence or unconsciousness;
n  tachycardia;
n  shortness of breath (apnoea) or decreased respiratory rate;
n  cyanosis;
n  miosis.
(52)  Simultaneously, details for two of these cases were also provided by the 
Swedish National Board of Forensic Medicine, Department of Forensic 
Genetics and Forensic Toxicology.
In four of the nine cases described by Helander et al. (2014), 
various neurological disturbances, such as paraesthesia in 
hands and feet, difficulties in grip and coordinating hand 
movements, balance disturbances, and/or blurred and 
double vision were also noted. Furthermore, bilateral hearing 
loss developed in three cases as a result of MT-45 exposure; 
in two of the cases the hearing impairment was transient, but 
in one case the unusual ototoxicity (53) persisted for two 
weeks after discharge, as documented at a follow-up 
audiology testing.
It is of importance that in serious overdose cases the judicious 
administration of the opioid receptor antagonist naloxone 
(total injected dose range: 0.1–2.0 mg) proved to be 
successful (Table 7).
In addition to the above non-fatal intoxications, Sweden also 
reported six other cases where MT-45 was mentioned but not 
confirmed analytically: in one of them (male, aged 24) the 
clinical symptoms (constricted pupils, somnolence, seizures 
and high body temperature) could have been due to the 
synthetic opioid AH-7921, which was detected in biological 
fluids. In another case (male, aged 24) no bioactive substance 
was reported or detected; treatment of the symptoms 
(unconsciousness and low blood oxygen saturation) consisted 
of naloxone administration and flumazenil as antidotes.
(53)  Opioid-induced hearing loss has been described but its etiology is unclear 
(Saifan et al, 2013; see also Helander et al., 2014).
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 t
re
at
m
e
n
t i
n
 h
o
sp
it
al
2
D
et
e
ct
e
d
D
ex
tr
o
m
et
h
o
rp
h
an
, 
m
et
h
io
p
ro
p
am
in
e 
(a
), 
T
H
C
N
o
t k
n
o
w
n
—
–
  C
o
n
st
ri
ct
e
d
 p
u
p
ils
, c
ya
n
o
si
s,
 u
n
co
n
sc
io
u
sn
e
ss
, t
a
ch
yc
ar
d
ia
. N
al
o
xo
n
e 
w
as
 
a
d
m
in
is
te
re
d
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t, 
re
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
3
D
et
e
ct
e
d
P
yr
a
zo
la
m
 (
b
), 
T
H
C
In
je
ct
e
d
 (
in
tr
av
e
n
o
u
s 
an
d
 
in
tr
am
u
sc
u
la
r)
 a
n
d
 
sn
o
rt
e
d
; 3
 g
 d
u
ri
n
g 
a 
w
e
e
k
α
-P
B
P
 (1
 g
) 
(c
); 
M
T-
4
5
 w
as
 
o
b
ta
in
e
d
 f
ro
m
 t
h
e 
In
te
rn
et
–
  S
o
m
n
o
le
n
ce
, h
yp
o
te
n
si
o
n
, t
a
ch
yc
ar
d
ia
, l
o
w
 o
xy
g
e
n
 s
at
u
ra
ti
o
n
. N
al
o
xo
n
e 
w
as
 
a
d
m
in
is
te
re
d
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t, 
re
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
4
D
et
e
ct
e
d
3
-M
e
O
-P
C
P
S
n
o
rt
e
d
‘M
ay
b
e 
so
m
e 
st
im
u
la
ti
n
g 
d
ru
g
s’
; M
T-
4
5
 w
as
 o
b
ta
in
e
d
 
fr
o
m
 t
h
e 
In
te
rn
et
–
  S
o
m
n
o
le
n
ce
, a
p
n
o
e
a,
 h
e
ar
in
g 
lo
ss
. N
al
o
xo
n
e 
w
as
 a
d
m
in
is
te
re
d
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t r
e
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
5
3
3
0
 m
g
/g
 
in
 b
lo
o
d
N
o
n
e
N
o
t k
n
o
w
n
—
–
  S
o
m
n
o
le
n
ce
, d
e
cr
e
as
e
d
 r
e
sp
ir
at
o
ry
 r
at
e,
 t
a
ch
yc
ar
d
ia
, h
e
ar
in
g 
lo
ss
, m
u
sc
u
la
r 
sy
m
p
to
m
s.
 N
al
o
xo
n
e 
w
as
 a
d
m
in
is
te
re
d
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t r
e
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
6
0
.0
6
 m
g
/g
 
in
 b
lo
o
d
F
lu
b
ro
m
a
ze
p
am
 (d
), 
T
H
C
N
o
t k
n
o
w
n
—
–
  S
o
m
n
o
le
n
ce
, t
a
ch
yc
ar
d
ia
–
  D
e
sc
ri
b
e
d
 b
o
th
 a
s 
lif
e
-t
h
re
at
e
n
in
g 
an
d
 n
o
n
 li
fe
-t
h
re
at
e
n
in
g 
e
ve
n
t b
y 
tw
o
 d
iff
e
re
n
t 
re
p
o
rt
in
g 
ag
e
n
ci
e
s;
 r
e
q
u
ir
e
d
 t
re
at
m
e
n
t i
n
 h
o
sp
it
al
7
D
et
e
ct
e
d
N
o
n
e
O
ra
l, 
re
ct
al
—
–
  S
o
m
n
o
le
n
ce
, d
e
cr
e
as
e
d
 r
e
sp
ir
at
o
ry
 r
at
e,
 t
a
ch
yc
ar
d
ia
.
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t, 
re
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
. O
u
tc
o
m
e 
n
o
t k
n
o
w
n
8
D
et
e
ct
e
d
N
o
n
e
N
o
t k
n
o
w
n
—
–
  U
n
co
n
sc
io
u
sn
e
ss
, h
yp
o
xi
a,
 v
o
m
it
in
g
, h
e
ar
in
g 
lo
ss
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t, 
re
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
9
D
et
e
ct
e
d
3
-M
M
C
/4
-M
M
C
 (e
), 
flu
b
ro
m
a
ze
p
am
 (d
), 
p
yr
a
zo
la
m
 (
b
)
O
ra
l (
p
o
w
d
e
r)
—
–
  U
n
co
n
sc
io
u
sn
e
ss
, d
e
cr
e
as
e
d
 r
e
sp
ir
at
o
ry
 r
at
e,
 h
yp
o
ka
la
e
m
ia
. N
al
o
xo
n
e 
w
as
 g
iv
e
n
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t, 
re
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
1
0
D
et
e
ct
e
d
α
-P
P
P
 (
f )
, N
-e
th
yl
b
u
p
h
e
d
ro
n
e 
(g
), 
α
-P
B
P
 (c
), 
3
-M
e
O
-P
C
P,
 
m
et
h
io
p
ro
p
am
in
e 
(a
)
O
ra
l (
ta
b
le
t)
F
lu
b
ro
m
a
ze
p
am
 (d
)
–
  S
o
m
n
o
le
n
ce
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t, 
re
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
11
D
et
e
ct
e
d
4
-h
yd
ro
xy
-m
id
a
zo
la
m
N
o
t k
n
o
w
n
—
–
  U
n
co
n
sc
io
u
sn
e
ss
, c
ya
n
o
si
s
–
  L
if
e
-t
h
re
at
e
n
in
g 
e
ve
n
t, 
re
q
u
ir
in
g 
tr
e
at
m
e
n
t i
n
 h
o
sp
it
al
1
2
D
et
e
ct
e
d
D
P
T
 (
h )
, d
e
sm
et
h
yl
d
ia
ze
p
am
N
o
t k
n
o
w
n
A
P
B
 (
i )
–
  A
n
xi
et
y,
 t
a
ch
yc
ar
d
ia
, h
al
lu
ci
n
at
io
n
s
–
  N
o
n
 li
fe
-t
h
re
at
e
n
in
g 
e
ve
n
t b
u
t r
e
q
u
ir
e
d
 t
re
at
m
e
n
t i
n
 h
o
sp
it
al
(a
) 
M
et
h
io
p
ro
p
am
in
e 
is
 a
 n
am
e 
fo
r 
a 
th
io
p
h
e
n
e
-c
o
n
ta
in
in
g 
an
al
o
g
u
e 
o
f 
m
et
h
am
p
h
et
am
in
e;
 it
 w
as
 fi
rs
t 
re
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 a
s 
a 
n
e
w
 p
sy
ch
o
a
ct
iv
e 
su
b
st
an
ce
 in
 J
an
u
ar
y 
2
0
11
.
(b
) 
P
yr
a
zo
la
m
 is
 a
 n
am
e 
fo
r 
a 
b
e
n
zo
d
ia
ze
p
in
e 
d
e
ri
va
ti
ve
; i
t 
w
as
 fi
rs
t 
re
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 a
s 
a 
n
e
w
 p
sy
ch
o
a
ct
iv
e 
su
b
st
an
ce
 in
 A
u
g
u
st
 2
0
1
2
.
(c
) 
α
-P
B
P
 is
 a
n
 a
cr
o
n
ym
 o
f 
a 
ca
th
in
o
n
e 
d
e
ri
va
ti
ve
; i
t 
w
a
s 
fi
rs
t 
re
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 a
s 
a 
n
e
w
 p
sy
ch
o
a
ct
iv
e 
su
b
st
an
ce
 in
 D
e
ce
m
b
e
r 
2
0
11
.
(d
) 
F
lu
b
ro
m
a
ze
p
am
 is
 a
 n
am
e 
fo
r 
a 
b
e
n
zo
d
ia
ze
p
in
e 
d
e
ri
va
ti
ve
; i
t 
w
as
 fi
rs
t 
re
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 a
s 
a 
n
e
w
 p
sy
ch
o
a
ct
iv
e 
su
b
st
an
ce
 in
 M
ar
ch
 2
0
1
3
.
(e
) 
 3
-M
M
C
 a
n
d
 4
-M
M
C
 a
re
 t
h
e 
ab
b
re
vi
a
ti
o
n
s 
o
f 
th
e 
re
sp
e
ct
iv
e 
re
g
io
is
o
m
e
rs
 o
f 
3
- 
o
r 
4
-m
e
th
yl
m
e
tc
a
th
in
o
n
e;
 t
h
e
y 
w
e
re
 fi
rs
t 
re
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 a
s 
‘n
e
w
 p
sy
ch
o
a
ct
iv
e 
su
b
st
an
ce
s’
 in
 S
e
p
te
m
b
e
r 
2
0
1
2
 a
n
d
 M
ar
ch
 2
0
0
8
, 
re
sp
e
ct
iv
e
ly
. Th
e 
a
ct
u
al
 is
o
m
e
r 
p
re
se
n
t 
in
 t
h
e 
b
io
lo
g
ic
al
 s
p
e
ci
m
e
n
 w
as
 n
o
t 
id
e
n
ti
fi
e
d
 in
 t
h
is
 c
as
e
.
(f
) 
N
-E
th
yl
b
u
p
h
e
d
ro
n
e 
is
 a
 n
am
e 
o
f 
a 
ca
th
in
o
n
e 
d
e
ri
va
ti
ve
; i
t 
w
as
 fi
rs
t 
re
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 a
s 
a 
n
e
w
 p
sy
ch
o
a
ct
iv
e 
su
b
st
an
ce
 in
 J
an
u
ar
y 
2
0
0
9
.
(g
) 
 α
-P
P
P
 is
 a
n
 a
cr
o
n
ym
 o
f 
a 
ca
th
in
o
n
e 
d
e
ri
va
ti
ve
; i
t 
w
as
 fi
rs
t 
re
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 a
s 
a 
n
e
w
 p
sy
ch
o
a
ct
iv
e 
su
b
st
an
ce
 in
 J
an
u
ar
y 
2
0
0
9
.
(h
) 
 D
P
T
 is
 a
n
 a
cr
o
n
ym
 f
o
r 
N
,N
-d
ip
ro
p
yl
tr
yp
ta
m
in
e;
 it
 w
as
 fi
rs
t 
w
a
s 
re
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 a
s 
a 
n
e
w
 p
sy
ch
o
a
ct
iv
e 
su
b
st
an
ce
 in
 N
o
ve
m
b
e
r 
2
0
0
4
.
(i )
  A
P
B
 p
ro
b
ab
ly
 s
ta
n
d
s 
fo
r 
an
 is
o
m
e
r 
o
f 
am
in
o
p
ro
p
yl
b
e
n
zo
fu
ra
n
s;
 t
h
e 
fi
rs
t 
o
f 
su
ch
 s
u
b
st
an
ce
s 
w
as
 r
e
p
o
rt
e
d
 t
o 
th
e 
E
M
C
D
D
A
 in
 D
e
ce
m
b
e
r 
2
0
1
0
.
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Annex 1
TA
B
L
E
 7
M
ai
n
 la
b
or
at
or
y 
an
d
 c
lin
ic
al
 fi
n
d
in
g
s 
fo
r 
n
on
-f
at
al
 in
to
xi
ca
ti
on
s 
re
p
or
te
d
 b
y 
H
el
an
d
er
 e
t 
al
. (
2
0
1
4
) 
w
h
er
e 
M
T-
4
5
 w
as
 a
n
al
yt
ic
al
ly
 c
on
fi
rm
ed
 in
 b
io
lo
g
ic
al
 s
am
p
le
s 
 
(u
ri
n
e 
or
 b
lo
o
d
 u
si
n
g
 L
C
/M
S
/M
S
).
 In
to
xi
ca
ti
on
s 
o
cc
u
rr
ed
 b
et
w
ee
n
 N
ov
em
b
er
 2
0
1
3
 a
n
d
 F
eb
ru
ar
y 
2
0
1
4
. A
ll 
ca
se
s 
w
er
e 
m
al
e,
 a
g
ed
 b
et
w
ee
n
 1
7
 a
n
d
 3
2
C
as
e
R
ep
or
te
d
 o
r 
su
sp
ec
te
d
 
su
b
st
an
ce
s 
(a
)
R
ep
or
te
d
 d
os
e 
an
d
 r
ou
te
 
of
 M
T-
4
5
 in
ta
ke
M
T-
4
5
 in
 
b
lo
od
 (n
g
/m
l)
M
T-
4
5
 in
 u
ri
n
e 
(n
g
/
m
m
ol
 c
re
at
in
in
e)
O
th
er
 s
u
b
st
an
ce
s 
d
et
ec
te
d
 in
 u
ri
n
e 
(a
)
M
ai
n
 c
lin
ic
al
 s
ym
p
to
m
s 
(b
);
 n
al
ox
on
e 
tr
ea
tm
en
t 
(c
),
 if
 a
n
y
1
M
T-
4
5
1
0
0
 m
g
; o
ra
l
6
5
.4
N
o
n
e
C
o
n
sc
io
u
s 
(R
L
S
 1
), 
p
ar
a
e
st
h
e
si
a 
in
 t
h
e 
ex
tr
e
m
it
ie
s;
—
2
M
T-
4
5
, a
lc
o
h
o
l
N
o
 in
fo
rm
at
io
n
1
0
2
4
3
T
H
C
-C
O
O
H
 (d
), 
d
ex
tr
o
m
et
h
o
rp
h
an
, 
m
et
h
io
p
ro
p
am
in
e
D
e
e
p
 u
n
co
n
sc
io
u
sn
e
ss
 (
R
L
S
 8
), 
re
sp
ir
at
o
ry
 d
e
p
re
ss
io
n
, c
ya
n
o
si
s,
 
m
io
si
s;
2
 x
 1
.0
 m
g 
n
al
o
xo
n
e
3
M
T-
4
5
, c
an
n
ab
is
, 
b
e
n
zo
fu
ra
n
s,
 p
yr
a
zo
la
m
, 
flu
b
ro
m
a
ze
p
am
, α
-P
V
P
 (e
), 
3
 g
 d
u
ri
n
g 
a 
w
e
e
k 
(in
 6
0
 m
g 
d
o
se
s)
; i
n
tr
av
e
n
o
u
s 
in
je
ct
io
n
, s
n
o
rt
e
d
1
9
0
T
H
C
-C
O
O
H
 (d
), 
p
yr
a
zo
la
m
D
e
p
re
ss
e
d
 le
ve
l o
f c
o
n
sc
io
u
sn
e
ss
 (
R
L
S
 3
), 
p
ro
lo
n
g
e
d
 lo
w
 o
xy
g
e
n
 
sa
tu
ra
ti
o
n
, v
is
io
n
 im
p
ai
rm
e
n
t;
1
 x
 0
.1
 m
g 
n
al
o
xo
n
e
4
M
T-
4
5
, m
et
h
io
p
ro
p
am
in
e,
 
p
h
e
n
cy
cl
id
in
e 
(P
C
P
)
U
n
kn
o
w
n
; d
o
se
 s
n
o
rt
e
d
3
9
2
0
0
3
-M
e
O
-P
C
P
D
e
e
p
 u
n
co
n
sc
io
u
sn
e
ss
 (
R
L
S
 5
), 
ap
n
o
e
a 
(r
e
q
u
ir
in
g 
in
tu
b
at
io
n
 a
n
d
 
as
si
st
e
d
 v
e
n
ti
la
ti
o
n)
, c
ya
n
o
si
s,
 m
io
si
s,
 h
e
ar
in
g 
im
p
ai
rm
e
n
t;
1
 x
 0
.4
 m
g 
n
al
o
xo
n
e
5
M
T-
4
5
N
o
 in
fo
rm
at
io
n
1
5
7
2
2
1
N
o
n
e
D
e
e
p
 u
n
co
n
sc
io
u
sn
e
ss
 (
R
L
S
 8
), 
re
sp
ir
at
o
ry
 d
e
p
re
ss
io
n
, h
an
d
 
w
e
ak
n
e
ss
, h
e
ar
in
g 
im
p
ai
rm
e
n
t;
3
 x
 0
.2
 +
 2
 x
 0
.1
 m
g 
n
al
o
xo
n
e
6
M
T-
4
5
, o
xy
co
d
o
n
e
N
o
 in
fo
rm
at
io
n
4
7
1
.7
T
H
C
-C
O
O
H
 (d
), 
flu
b
ro
m
a
ze
p
am
D
e
p
re
ss
e
d
 le
ve
l o
f c
o
n
sc
io
u
sn
e
ss
 (
R
L
S
 2
);
—
7
M
T-
4
5
 (
f )
U
n
kn
o
w
n
; d
o
se
 t
ak
e
n
 o
ra
lly
 
an
d
 r
e
ct
al
ly
6
5
3
5
N
o
n
e
D
e
p
re
ss
e
d
 le
ve
l o
f c
o
n
sc
io
u
sn
e
ss
 (
R
L
S
 2
), 
p
ro
lo
n
g
e
d
 lo
w
 o
xy
g
e
n
 
sa
tu
ra
ti
o
n
,
U
n
sp
e
ci
fie
d
 d
o
se
 o
f n
al
o
xo
n
e 
w
as
 g
iv
e
n
8
M
T-
4
5
U
n
kn
o
w
n
; d
o
se
 
a
d
m
in
is
te
re
d
 o
ra
lly
 o
r 
b
y 
in
tr
av
e
n
o
u
s 
in
je
ct
io
n
4
5
0
.6
N
o
n
e
D
e
e
p
 u
n
co
n
sc
io
u
sn
e
ss
 (
R
L
S
 8
), 
ap
n
o
e
a,
 m
io
si
s,
 le
ft
 v
e
n
tr
ic
u
la
r 
d
ys
fu
n
ct
io
n
, p
ro
lo
n
g
e
d
 lo
w
 o
xy
g
e
n
 s
at
u
ra
ti
o
n
 a
n
d
 r
e
sp
ir
at
o
ry
 
d
e
p
re
ss
io
n
, s
e
ve
ra
l n
e
u
ro
lo
g
ic
al
 d
is
tu
rb
an
ce
s 
in
cl
u
d
in
g 
h
e
ar
in
g 
lo
ss
;
1
 x
 0
.4
 m
g 
n
al
o
xo
n
e
9
M
T-
4
5
1
0
0
 m
g
, o
ra
l
5
6
1
3
2
3
-M
M
C
, p
yr
a
zo
la
m
D
e
e
p
 u
n
co
n
sc
io
u
sn
e
ss
 (
R
L
S
 8
), 
p
ro
lo
n
g
e
d
 r
e
sp
ir
at
o
ry
 d
e
p
re
ss
io
n
;
3
 x
 0
.4
 m
g 
n
al
o
xo
n
e
(a
) 
F
o
r 
ex
p
la
n
a
ti
o
n
 o
f 
n
am
e
s 
an
d
 a
b
b
re
vi
a
ti
o
n
s,
 s
e
e 
Ta
b
le
 6
.
(b
) 
 U
se
d
 a
lm
o
st
 e
xc
lu
si
ve
ly
 in
 S
w
e
d
e
n
, t
h
e 
R
e
a
ct
io
n
 L
e
ve
l S
ca
le
 (
R
L
S
8
5
) 
is
 a
n
 e
ig
h
t-
g
ra
d
e 
co
m
a 
sc
al
e 
fo
r 
d
ir
e
ct
 b
e
d
si
d
e 
as
se
ss
m
e
n
t 
o
f 
co
n
sc
io
u
sn
e
ss
 o
r 
o
ve
ra
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D1.2.3. MT-45 associated deaths 
Since November 2013, when the first death associated with 
MT-45 use was reported by Sweden, a total of 28 deaths 
where MT-45 was detected have been reported from one 
Member State, Sweden (EMCDDA and Europol, 2014). All but 
one of the death cases were males aged between 19 and 59; 
the one female was 23 years old. Forensic information on 
these deaths, which occurred within a nine-month period 
between November 2013 and July 2014 and typically in a 
home environment, are summarised below and tabulated in 
Table 8. 
MT-45 was analytically confirmed in all the death cases 
reported by the Swedish National Board of Forensic 
Medicine (Department of Forensic Genetics and Forensic 
Toxicology, Linköping). In four of these cases MT-45 was the 
sole detected drug in post-mortem femoral blood at 
concentrations ranging from 0.2 to 1.9 mg/g (54). In one 
additional case where MT-45 was the sole detected drug in 
post-mortem femoral blood (0.15 mg/g), death was due to an 
accident (‘injury’). In the remaining 24 cases at least one 
other psychoactive substance was detected. These included: 
THC (one case); ethanol (four cases); stimulants (six cases); 
(54)  For comparison, in fatal heroin or morphine poisoning cases the reported 
blood concentrations range from 0.04 to 3.0 mg/L (Musshoff et al., 2004; 
Moffatt et al., 2011; Häkkinen et al., 2012). 
benzodiazepines and/or their metabolites (13 cases); other 
opioids (10 cases); as well as other medicines and, in some 
cases, their metabolites: alimemazine (also known as 
trimeprazine) or levomepromazine (also known as 
methotrimeprazine), bupropion, citalopram, duloxetine, 
fluoxetine, gabapentin, lamotrigine, metoclopramide, 
mirtazapine, olanzapine, promethazine, propranolol, 
quetiapine, sertraline, venlafaxine and/or zopiclone (one or 
more of these in 14 cases). In the polydrug intoxications, the 
concentration of MT-45 in post-mortem femoral blood 
ranged from 0.006 to 1.7 mg/g. (See Table 8 for further 
details.)
For 22 cases the cause of death was given as follows: ‘MT-45 
intoxication’ (eight cases); ‘mixed intoxication’ (six cases); 
‘mixed intoxication’ specifying ‘opioids’ (one case), ‘opiates 
and illicit drugs’ (one case) and ‘tramadol and MT-45’ (one 
case); ‘ethanol and drugs’ intoxication (one case); 
‘alimemazine, MT-45 and diclazepam’ intoxication (one case); 
and ‘pneumonia + intoxication’ (two cases). As mentioned in 
the previous paragraph, one death was due to a fatal accident. 
For six cases the cause of death has not been declared (as of 
September 2014).
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In an attempt to evaluate the toxicological significance of 
MT-45 in the deaths reported, an assessment of the 
following evidence was considered in each case: presence 
and concentration (and pharmacological nature) of MT-45; 
presence and concentration (and pharmacological nature) of 
other drugs present (including alcohol); circumstances of 
death; and cited cause of death. This allowed the 
significance of MT-45 in the deaths to be categorised as of 
low significance (i.e. alternative cause of death), medium 
significance (i.e. MT-45 may have contributed to toxicity/
death but other drugs present may have been more 
toxicologically significant) or high significance (i.e. MT-45 
was cited as the cause of death or was assessed as being 
likely to have contributed to toxicity/death even in the 
presence of other drugs). In order to highlight potential 
interactions or contributing toxicology the other substances 
found in the cases were characterised.
In 19 deaths MT-45 was reported either as the cause of death 
or as contributing to death (even in presence of other 
substances); in three of these deaths MT-45 was the sole drug 
present. In eight deaths MT-45 may have contributed to 
toxicity but other substances were present that may have 
been more toxicologically significant. An alternative cause of 
death was recorded in one case (the deceased had jumped off 
a building). In the cases where other substances were found 
these included opioids, benzodiazepines (both authorised and 
unauthorised medicinal products), stimulants and other 
prescription medicines (including antipsychotics, 
antidepressants, and anticonvulsants).
Deaths identified in open source information
Two deaths from the United States of America that occurred 
between 7 and 10 August 2013 were identified in a news 
release by the US Immigration and Customs Enforcement’s 
Homeland Security Investigations (EMCDDA and Europol, 
2014). These deaths involved a male (aged 34) and a female 
(aged 33) who were found dead in their apartment in 
Hamburg, New York State; white powder identified as MT-45 
was recovered at the scene. The medical examiner determined 
that the male had died of acute intoxication with MT-45 and 
the female had died of acute intoxication with MT-45 and 
ethanol (55). Documented evidence showed that 3 g of MT-45 
had been ordered through the Internet on 29 July 2013 and 
received by the victims on 5 August 2013. Diazepam and 
oxycodone were also collected at the scene.
(55)  www.ice.gov/news/releases/1404/140411buffalo.htm and personal 
communication to EMCDDA from US Immigration and Customs 
Enforcement’s Homeland Security Investigations.
I D2. Chronic health effects
D2.1. Animal data
There is no animal data in the scientific or grey literature on 
the chronic health effects of MT-45.
There are no data on the neurotoxicity or carcinogenicity of 
MT-45 in vitro. It could be relevant to mention, however, that in 
the in vivo anticancer drug screening programme of the 
National Cancer Institute (NCI), USA, intraperitoneally 
administered MT-45, under NCI number code NSC 299236, 
did not show antitumour activity in two strains of mice bearing 
transplantable tumours (P388 leukemia) (NCBI, 2014).
D2.2. Human data
There are no published studies investigating the chronic 
health effects of MT-45 in humans.
I D3. Factors affecting public health risks 
D3.1. Availability and quality of the new psychoactive 
substance on the market (purity, adulterants, etc.)
MT-45 is offered for sale in small (multi gram) and in bulk 
(kilogram) quantities on the Internet by several suppliers as a 
drug in its own right (Section C). The purity of these products 
is claimed to be high (>95 %) but this has rarely been tested 
by forensic analysis. Racemic and enantiopure MT-45 have 
become commercially available as analytical standards or 
experimental research chemicals from several fine chemical 
suppliers (56). 
Analyses of seized products indicate that adulterants are not 
typically present in the powder products offered as MT-45. 
(Adulterants or contaminants arising from manufacture could 
be present in products but these are either not detected or not 
reported.) However, in two powder samples (0.1 g and 9 g) 
seized by customs in Sweden the stimulants 6-APDB and 
α-PBP were also detected. Furthermore, MT-45 was detected 
as an added component in powder, herbal and liquid products, 
along with other psychoactive substances as noted in Belgium 
and Germany, and in Japan. See Section C for details on 
seized and collected samples.
(56)  For example, bioreagent.bertinpharma.com or www.caymanchem.com
RISK ASSESSMENTS I MT-45
36 / 48
Annex 1
D3.2. Availability of the information, degree of 
knowledge and perceptions amongst users concerning 
the psychoactive substance and its effects
There is limited information on commonly used user websites 
regarding the effects and potential health/adverse effects 
related to the use of MT-45 (Section D1.2.1). The users and 
forum discussion participants appear to be generally aware of 
the opioid-like (wanted and unwanted) effects of this 
substance.
D3.3. Characteristics and behaviour of users (including 
risk factors, vulnerability, etc.)
No studies were identified that have examined the 
characteristics and behaviour of MT-45 users. Available 
information, including forensic reports from Sweden (see also 
Helander et al., 2014) and from self-reports originating from 
user websites indicate that MT-45 is typically used in the 
home environment. Some users are simply experimenting with 
this new drug, some use it to self-medicate pain or opioid-
withdrawal symptoms. It also apparent from these reports that 
polydrug use is common.
D3.4. Nature and extent of health consequences (e.g. 
acute emergencies, road traffic accidents)
The limited information on the acute health effects of MT-45 in 
humans has been discussed in Section D1.2. Based on animal 
model experiments (Section A2) as well as on self-reports and 
clinical cases (Section D1.2), it may, however, be assumed 
that the acute behavioural effects of MT-45 on operating 
machinery and driving are similar to those caused by other 
opioid-type narcotic-analgesics.
There is insufficient information in the reported deaths where 
MT-45 has been detected to discuss in detail the 
circumstances of these deaths. From the information 
available, it does not appear that any of these were related to 
work or road traffic accidents. MT-45 was the sole drug 
detected in a fatal accident (a 22-year-old male jumped or fell 
off a building), but the events preceding or the circumstances 
of the accident are unknown.
D3.5. Long-term consequences of use 
As discussed in Sections D2.1 and D2.2, there are no animal 
or human data on the chronic health effects of MT-45 use.
D3.6. Conditions under which the new psychoactive 
substance is obtained and used, including context-
related effects and risks 
Based on user reports and Internet searches, MT-45, being an 
unregulated substance in most Member States, is openly 
advertised as a ‘new research chemical’ or ‘legal opioid’. The 
amount offered by Internet retailers ranged from 1 g to 
kilogram quantities (see also Section C).
As mentioned, the available information suggests that MT-45 
is typically used in the home environment, either alone or in 
the company of a close friend (i.e. MT-45 does not appear to 
be a ‘party drug’).
I Section E. Social risks
I E1. Individual social risks
There are no published data to be able to determine the 
impact of MT-45 in this area.
I E2. Possible effects on direct social environment 
There are no published data to be able to determine the 
impact of MT-45 in this area.
I E3. Possible effects on society as a whole
There are no published data to be able to determine the 
impact of MT-45 in this area. 
One Member State (Sweden) reported the detection of MT-45 
in two ‘petty drug offence’ cases. In one case, which occurred 
in December 2013, MT-45 was found in blood (0.08 mg/g) 
along with alprazolam, buprenorphine, flubromazepam, 
flunitrazepam, morphine and pyrazolam. The other case 
occurred in March 2014 and MT-45 was confirmed by LC/MS 
(TOF) in the urine but no quantification was done; 
buprenorphine and its nor-metabolite were also detected.
I E4. Economic costs 
Given the lack of data available on acute health emergencies 
and healthcare utilisation related to the use of MT-45, it is not 
possible at this time to estimate whether this substance is 
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associated with greater healthcare costs than other opioid 
drugs. 
I  E5. Possible effects related to the cultural context, for example marginalisation
There are no published data to be able to determine the 
impact of MT-45 in this area.
I  E6. Possible appeal of the new psychoactive substance to specific population groups within the general population
At this time, there does not appear to be any appeal related to 
the use of MT-45 within the general population, or even within 
sub-populations that are usually associated with higher use of 
recreational drugs and new psychoactive substances.
I Section F. Involvement of organised crime
I  F1. Evidence that criminal groups are systematically involved in production, trafficking and distribution for financial gain
There is no specific information that criminal groups are 
systematically involved in the production, trafficking and/or 
distribution of MT-45 for financial gain (EMCDDA and Europol, 
2014).
There is no information indicating the production of MT-45 in 
any of the Member States, Turkey or Norway.
I  F2. Impact on the production, trafficking and distribution of other substances, including existing psychoactive substances as well as new psychoactive substances
There is nothing to suggest that distribution networks 
established for heroin are being used. Based on the 
information available to the ECMDDA and Europol, the 
production, trafficking and distribution of MT-45 does not 
appear to have any impact on other existing psychoactive 
substances or new psychoactive substances. However, the 
detection in Germany of MT-45 in a ‘brown heroin’ mixture 
also containing typical adulterants (caffeine, paracetamol and 
sorbitol) could be an indication of MT-45 and heroin having a 
common source possibly associated with a criminal 
organisation.
I  F3. Evidence of the same groups of people being involved in different types of crime
There is no information available in this area.
I  F4. Impact of violence from criminal groups on society as a whole or on social groups or local communities (public order and safety)
No information has been received by Europol on incidents of 
violence in connection specifically with MT-45.
I  F5. Evidence of money laundering practices, or impact of organised crime on other socioeconomic factors in society
No information has been received by Europol on incidents of 
money laundering specifically in connection with MT-45.
I  F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial system)
There are no published data to be able to determine the 
impact of MT-45 in this area.
I F7. Use of violence between or within criminal groups
There are no published data to be able to determine the 
impact of MT-45 in this area. 
I  F8. Evidence of strategies to prevent prosecution, for example through corruption or intimidation 
There are no published data to be able to determine the 
impact of MT-45 in this area. 
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COUNCIL IMPLEMENTING DECISION (EU) 2015/1873 of 8 October 2015 on subjecting 
4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR) and 1-cyclohexyl-
4-(1,2-diphenylethyl)piperazine (MT-45) to control measures
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk-assessment and control of new psychoactive substances (1), and in 
particular Article 8(3) thereof,
Having regard to the proposal of the European Commission,
Having regard to the opinion of the European Parliament,
Whereas:
(1) A Risk Assessment Report on the new psychoactive substance 4-methyl-5-(4-
methylphenyl)-4,5-dihydrooxazol-2- amine (4,4′-DMAR) was drawn up in accordance with 
Article 6 of Decision 2005/387/JHA by a special session of the extended Scientific 
Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
and was subsequently submitted to the Commission and to the Council on 19 September 
2014.
(2) 4,4′-DMAR is a synthetic substituted oxazoline derivative. It is a derivative of aminorex 
and 4-methylaminorex (4-MAR), two synthetic stimulants controlled under the 1971 United 
Nations Convention on Psychotropic Substances.
(3) 4,4′-DMAR has been available on the drugs market in the Union since at least 
December 2012 and was notified to the Early Warning System in December 2012. Nine 
Member States have reported detections as a result of seizures of the substance, mainly in 
the form of white or coloured powders and tablets, as well as biological and collected 
samples.
(4) 4,4′-DMAR emerged on the new psychoactive substances market as a ‘research 
chemical’ sold by internet retailers, and it is now available on the street market. 4,4′-DMAR 
is being sold and consumed as a substance on its own, but it has also been mis-sold on 
the illicit market as ecstasy and amphetamines.
(5) There have been 31 deaths associated with 4,4′-DMAR registered in three Member 
States, between June 2013 and June 2014. In most cases, 4,4′-DMAR was either the 
cause of death or, together with other substances, is likely to have contributed to death. 
One Member State has reported a case of non-fatal intoxication.
(6) There are no studies on the toxicity of 4,4′-DMAR.
(7) There is no prevalence data on the use of 4,4′-DMAR. However, the information 
available suggests that it has not been widely used. Information obtained from cases 
(1) OJ L 127, 20.5.2005, p. 32.
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involving death also suggests that users unknowingly consumed 4,4′-DMAR when seeking 
other stimulants.
(8) There is limited involvement of organised crime in the manufacture, distribution, 
trafficking and supply of 4,4′-DMAR within the Union. The chemical precursors and the 
synthetic routes used to manufacture 4,4′-DMAR are unknown.
(9) 4,4′-DMAR is not listed for control under the 1961 United Nations Single Convention on 
Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances. 
It is not currently under assessment, and has not been under assessment, by the United 
Nations’ system, and no such assessment is planned. (10) 4,4′-DMAR has no established 
or acknowledged human or veterinary medical use in the Union. Apart from its use in 
analytical reference materials, and in scientific research investigating its chemistry, 
pharmacology and toxicology, there is no indication that it is being used for other 
purposes.
(11) The Risk Assessment Report reveals that there is limited scientific evidence available 
on 4,4′-DMAR and points out that further research would be needed to determine the 
health and social risks that it poses. However, the evidence and information currently 
available provides sufficient ground for subjecting 4,4′-DMAR to control measures across 
the Union. As a result of the risks to health that the consumption of 4,4′-DMAR poses, as 
documented by its detection in several fatalities, of the fact that users may unknowingly 
consume it, and of the lack of medical value of this substance, 4,4′-DMAR should be 
subjected to control measures.
(12) Given that three Member States control 4,4′-DMAR under national legislation 
complying with the obligations of the 1971 United Nations Convention on Psychotropic 
Substances and five Member States use other legislative measures to control it, subjecting 
this substance to control measures across the Union would help avoid the emergence of 
obstacles in cross-border law enforcement and judicial cooperation, and would protect 
against the risks that its availability and use can pose.
(13) A Risk Assessment Report on the new psychoactive substance 1-cyclohexyl-4-(1,2-
diphenylethyl)piperazine (MT-45) was drawn up in accordance with Article 6(2), (3) and (4) 
of Decision 2005/387/JHA by a special session of the extended Scientific Committee of 
the EMCDDA, and was subsequently submitted to the Commission and to the Council on 
6 October 2014.
(14) MT-45 is an N,N′-disubstituted piperazine, having a cyclohexane ring attached to one 
of the nitrogen atoms of the piperazine ring and a 1,2-diphenylethyl moiety attached to the 
other nitrogen atom. MT-45 is one of a series of 1-(1,2-diphenylethyl)piperazine analgesics 
invented in the early 1970s.
(15) MT-45 has been present on the drugs market in the Union since October 2013, where 
it is sold as a ‘research chemical’, mostly on the internet. The EMCDDA has identified 12 
sites of internet suppliers and retailers that have offered MT-45 for sale, including some 
apparently based in the Union.
(16) A total of 28 fatalities occurring between November 2013 and July 2014 have been 
reported by one Member State. In most cases, the presence of MT-45 in biological 
samples was analytically confirmed. Some 18 non-fatal intoxications have also been 
reported by the same Member State, the clinical features of which were similar to opioid 
intoxication, responding in some cases to the opioid receptor antagonist naloxone.
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(17) There are several studies in animals indicating that the acute toxicity of MT-45 is 
several-fold higher than that of morphine.
(18) Currently available information suggests that MT-45 has not been widely used. The 
substance appears to be mostly used in the home environment either by users willing to 
try a new substance or by opioid dependent users with no access to heroin or any other 
opioid. Users may combine MT-45 with other psychoactive substances. There is no 
information on the social risks that may be related to MT-45.
(19) There is no evidence of involvement of organised crime in the manufacture, 
distribution, trafficking and supply of MT-45 in the Union. The chemical precursors and the 
synthetic routes used to manufacture the MT-45 detected in Member States are unknown.
(20) MT-45 is not listed for control under the 1961 United Nations Single Convention on 
Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances. 
It is not currently under assessment, and has not been under assessment, by the United 
Nations’ system, and no such assessment is planned.
(21) MT-45 has no established or acknowledged human or veterinary medical use in the 
Union. Apart from its use in analytical reference materials, and in scientific research 
investigating its chemistry, pharmacology and toxicology, there is no indication that it is 
being used for other purposes.
(22) The Risk Assessment Report reveals that there is limited scientific evidence available 
on MT-45 and points out that further research would be needed to determine the health 
and social risks that it poses. However, the evidence and information currently available 
provides sufficient grounds for subjecting MT-45 to control measures across the Union. As 
a result of the health risks that it poses, as documented by its detection in several 
fatalities, and of the lack of medical value of this substance, MT-45 should be subjected to 
control measures.
(23) Given that one Member State controls MT-45 under national legislation complying 
with the obligations under the 1961 United Nations Single Convention on Narcotic Drugs 
and under the 1971 United Nations Convention on Psychotropic Substances and seven 
Member States use other legislative measures to control it, subjecting this substance to 
control measures across the Union would help avoid the emergence of obstacles in 
cross-border law enforcement and judicial cooperation, and would protect against the risks 
that its availability and use can pose.
(24) Decision 2005/387/JHA confers upon the Council implementing powers with a view 
to giving a quick and expertise-based response at Union level to the emergence of new 
psychoactive substances detected and reported by the Member States, by subjecting 
those substances to control measures across the Union. As the conditions and procedure 
for triggering the exercise of such implementing powers have been met, an implementing 
decision should be adopted in order to put 4,4′-DMAR and MT-45 under control across the 
Union.
(25) Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision which implements Decision 2005/387/JHA.
(26) Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision which implements Decision 2005/387/JHA.
RISK ASSESSMENTS I MT-45
44 / 48
Council Decision
(27) The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not 
taking part in the adoption of this Decision which implements Decision 2005/387/JHA and 
is not bound by it or subject to its application,
HAS ADOPTED THIS DECISION:
Article 1
The following new psychoactive substances shall be subjected to control measures across 
the Union:
(a) 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR);
(b) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45).
Article 2
By 21 October 2016, Member States shall take the necessary measures, in accordance 
with their national law, to subject the new psychoactive substances referred to in Article 1 
to control measures and criminal penalties, as provided for under their legislation 
complying with their obligations under the 1961 United Nations Single Convention on 
Narcotic Drugs and/or under the 1971 United Nations Convention on Psychotropic 
Substances.
Article 3
This Decision shall enter into force on the day following that of its publication in the Official 
Journal of the European Union.
This Decision shall apply in accordance with the Treaties.
Done at Luxembourg, 8 October 2015.
For the Council 
The President 
J. ASSELBORN 
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Abbreviations
(R) Levorotatory (rectus)
(S) Dextrorotatory (sinister)
[α]22
D
Optical Rotation
3-MeO-PCP 3-Methoxyphencyclidine
3-MMC 3-Methylmethcathinone
4-F-PVP 4-Fluoro-Pyrrolidinovalerophenone
4-MMC 4-Methylmethcathinone
6-APB 6-(2-Aminopropyl)benzofuran
6-APDB 6-(2-Aminopropyl)-2,3-dihydrobenzofuran
6-MAPB 1-(Benzofuran-6-yl)-N-methylpropan-2-amine
AB-FUBINACA N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide
AH-7921 3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]
methyl]benzamide
APB (2-Aminopropyl)benzofuran
APDB (2-Aminopropyl)-2,3-dihydrobenzofuran
API Active pharmaceutical ingredient
APINACA 
(AKB48)
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-
carboxamide
CAS Chemical Abstracts Service registry number
CDEP 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine
DADLE D-Ala2,D-Leu5enkephalin
Decision Council Decision 2005/387/JHA of 10 May 
2005 on the information exchange, risk 
assessment and control of new psychoactive 
substances
DHM Dihydromorphine
DOP δ Opioid peptide
DPT N,N-Dipropyltryptamine
ECHA European Chemicals Agency
ED
50
Half maximal effective dose
EKC Ethyl-ketocyclazocine
EMA European Medicines Agency 
ESPAD European School Survey Project on Alcohol and 
other Drugs
EU European Union
EUR Euro
EWS Early Warning System (EMCDDA–Europol)
GC Gas chromatography 
GC-MS Gas chromatography-mass spectrometry
i.v Intravenous
Abbreviations
IC
50
Half maximal inhibitory concentration
IC-6 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine
I-C6 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine
IUPAC International Union of Pure and Applied 
Chemistry
KOP κ Opioid peptide
LC Liquid chromatography
LC-MS/MS Liquid chromatography tandem mass 
spectrometry 
LD
50
Median lethal dose
MDMA 3,4-Methylenedioxymethamphetamine
MOP μ Opioid peptide
MS Mass spectrometry
MT-45 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine 
NCBI National Centre for Biotechnology Information
NCI National Cancer Institute
NEDPA N-Ethyl-1,2-diphenylethylamine
NLX Naloxone
NMDA N-Methyl-D-aspartate
NMR Nuclear magnetic resonance spectroscopy
NPDPA N-(1,2-Diphenylethyl)propan-2-amine
NPSG Austrian Law on New Psychoactive Substances 
NSC National Service Centre 
NSC299236 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine
REACH Regulation on registration, evaluation, 
authorisation and restriction of chemicals, 
database hosted by European Chemicals 
Agency
RLS Reaction level scale
RTECS Registry of Toxic Effects of Chemical Substances
s.c Subcutaneous
THC Tetrahydrocannabinol
THC-COOH Tetrahydrocannabinol-carboxylic acid
TOF Time-of-flight
UN United Nations
USD United States Dollars
WHO World Health Organization
α-PBP α-Pyrrolidinobutyrophenone
α-PPP α-Pyrrolidinopropiophenone
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